Cardinal Health, Inc. (CAH)
Dublin, OH, US
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
5 articles
- Looking for a Growth Stock? 3 Reasons Why Cardinal (CAH) is a Solid Choice Zacks Investment Research
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Sections | — | 1995-10-10 | View |
| Behrens | — | 1996-03-25 | View |
| Owen | OWN | 1997-02-12 | View |
| MediQual | — | 1997-07-08 | View |
| Virtus LifeSci Biotech Clinical Trials ETF | BBC | 1998-01-21 | View |
| Bergen | — | 1998-06-12 | View |
| Bergen Brunswig | — | 1998-12-14 | View |
| Bindley | BDY | 2001-01-08 | View |
| Syncor | — | 2002-10-16 | View |
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1997-05-23 | — | Active |
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.03% | -4.72% | -15.29% | -15.11% | -10.65% | -11.16% | +22.84% | +115.36% | +227.11% | +137.09% | +20,178.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 12 | 0 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
248.00
+6.1%
|
| Last Quarter | 4 |
255.25
+9.2%
|
| Last Year | 25 |
229.04
-2.0%
|
| All Time | 53 |
160.92
-31.1%
|
-
Revenue growth Medical - Distribution: +5.6%-1.9% Q1'26: +11.0% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+87.0% ★ Q1'26: -19.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+0.6% Q1'26: +2.8% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+1.0% Q1'26: +0.8% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+61.0% ★ Q1'26: +85.6% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-2.0% ★ Q1'26: -2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×3.01× Q1'26: 2.94× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 12 Rev. Ana. 10 EPS Ana. |
Jun 2027 12 Rev. Ana. 11 EPS Ana. |
Jun 2028 12 Rev. Ana. 5 EPS Ana. |
Jun 2029 10 Rev. Ana. 1 EPS Ana. |
Jun 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
102.64B
est: 87.54B (+17.2%)
|
107.55B
est: 99.91B (+7.6%)
|
101.09B
est: 100.18B (+0.9%)
|
91.08B
est: 91.32B (-0.3%)
|
102.53B
est: 100.98B (+1.5%)
|
121.55B
est: 121.28B (+0.2%)
|
129.98B
est: 129.70B (+0.2%)
|
136.81B
est: 135.79B (+0.7%)
|
145.53B
est: 144.88B (+0.5%)
|
152.92B
est: 153.20B (-0.2%)
|
162.47B
est: 160.21B (+1.4%)
|
181.33B
est: 178.77B (+1.4%)
|
204.98B
est: 204.30B (+0.3%)
|
226.83B
est: 225.71B (+0.5%)
|
222.58B
est: 223.26B (-0.3%)
|
256.05B
254.62B – 257.99B
+14.7% YoY
|
277.11B
271.88B – 282.42B
+8.2% YoY
|
299.22B
298.77B – 299.67B
+8.0% YoY
|
322.74B
316.72B – 327.65B
+7.9% YoY
|
339.07B
332.74B – 344.23B
+5.1% YoY
|
| EBITDA |
1.92B
est: 1.54B (+24.6%)
|
2.12B
est: 1.81B (+16.7%)
|
1.41B
est: 2.15B (-34.4%)
|
2.39B
est: 1.37B (+74.4%)
|
2.56B
est: 2.24B (+14.2%)
|
3.10B
est: 2.63B (+17.7%)
|
2.84B
est: 2.87B (-1.0%)
|
1.13B
est: 2.27B (-50.1%)
|
3.05B
est: 1.54B (+97.7%)
|
-2.62B
est: -2.77B (+5.3%)
|
1.29B
est: 1.86B (-31.0%)
|
55.00M
est: 997.53M (-94.5%)
|
1.44B
est: 421.53M (+241.4%)
|
1.96B
est: 5.43B (-63.9%)
|
3.11B
est: 5.37B (-42.2%)
|
6.16B
6.13B – 6.21B
+14.7% YoY
|
6.67B
6.54B – 6.79B
+8.2% YoY
|
7.20B
7.19B – 7.21B
+8.0% YoY
|
7.76B
7.62B – 7.88B
+7.9% YoY
|
8.16B
8.00B – 8.28B
+5.1% YoY
|
| EBIT |
1.61B
est: 1.22B (+32.2%)
|
1.79B
est: 1.54B (+16.3%)
|
1.01B
est: 1.80B (-43.8%)
|
1.93B
est: 928.57M (+108.0%)
|
2.11B
est: 1.83B (+15.3%)
|
2.45B
est: 2.14B (+14.9%)
|
2.13B
est: 2.24B (-5.0%)
|
101.00M
est: 1.50B (-93.3%)
|
2.05B
est: 671.15M (+204.7%)
|
-3.53B
est: -3.57B (+0.9%)
|
503.00M
est: 672.91M (-25.3%)
|
-637.00M
est: 202.72M (-414.2%)
|
747.00M
est: -406.10M (+283.9%)
|
1.25B
est: 4.99B (-74.9%)
|
2.32B
est: 4.93B (-53.0%)
|
5.66B
5.63B – 5.70B
+14.7% YoY
|
6.12B
6.01B – 6.24B
+8.2% YoY
|
6.61B
6.60B – 6.62B
+8.0% YoY
|
7.13B
7.00B – 7.24B
+7.9% YoY
|
7.49B
7.35B – 7.60B
+5.1% YoY
|
| Net Income |
959.00M
est: 821.25M (+16.8%)
|
1.07B
est: 877.20M (+21.9%)
|
334.00M
est: 1.09B (-69.3%)
|
1.17B
est: 322.29M (+261.8%)
|
1.22B
est: 1.06B (+14.5%)
|
1.43B
est: 1.25B (+14.3%)
|
1.29B
est: 1.28B (+0.4%)
|
256.00M
est: 1.45B (-82.3%)
|
1.36B
est: -84.12M (+1,720.4%)
|
-3.69B
est: -3.58B (-3.3%)
|
611.00M
est: 1.20B (-49.3%)
|
-938.00M
est: 601.41M (-256.0%)
|
330.00M
est: 156.00M (+111.5%)
|
852.00M
est: 1.78B (-52.1%)
|
1.56B
est: 1.98B (-21.1%)
|
2.57B
2.52B – 2.63B
+30.0% YoY
|
2.89B
2.82B – 2.97B
+12.5% YoY
|
3.14B
2.47B – 3.82B
+8.7% YoY
|
3.64B
3.55B – 3.71B
+15.6% YoY
|
4.34B
4.23B – 4.42B
+19.3% YoY
|
| SGA |
2.59B
est: 2.14B (+21.4%)
|
2.68B
est: 2.46B (+8.8%)
|
2.88B
est: 2.65B (+8.4%)
|
3.03B
est: 2.81B (+7.9%)
|
3.24B
est: 2.99B (+8.2%)
|
3.65B
est: 3.14B (+16.1%)
|
3.78B
est: 3.53B (+6.9%)
|
4.60B
est: 3.58B (+28.2%)
|
4.48B
est: 4.18B (+7.1%)
|
4.57B
est: 3.73B (+22.7%)
|
4.53B
est: 3.66B (+23.8%)
|
4.51B
est: 4.91B (-8.1%)
|
4.80B
est: 5.35B (-10.2%)
|
5.00B
est: 5.53B (-9.5%)
|
5.38B
est: 5.47B (-1.5%)
|
6.27B
6.23B – 6.32B
+14.7% YoY
|
6.79B
6.66B – 6.92B
+8.2% YoY
|
7.33B
7.32B – 7.34B
+8.0% YoY
|
7.90B
7.75B – 8.02B
+7.9% YoY
|
8.30B
8.15B – 8.43B
+5.1% YoY
|
| EPS |
2.75
est: 1.90 (+44.7%)
|
3.10
est: 2.55 (+21.6%)
|
0.98
est: 3.09 (-68.3%)
|
3.42
est: 3.21 (+6.5%)
|
3.66
est: 4.37 (-16.2%)
|
4.36
est: 5.23 (-16.7%)
|
4.06
est: 5.35 (-24.1%)
|
0.82
est: 4.93 (-83.4%)
|
4.54
est: 5.10 (-11.0%)
|
-12.60
est: 5.30 (-337.6%)
|
2.09
est: 5.99 (-65.1%)
|
-3.34
est: 5.19 (-164.4%)
|
1.26
est: 5.74 (-78.1%)
|
3.48
est: 7.36 (-52.7%)
|
6.48
est: 8.20 (-20.9%)
|
10.74
10.40 – 10.85
+31.1% YoY
|
11.99
11.64 – 12.26
+11.6% YoY
|
13.52
10.19 – 15.80
+12.8% YoY
|
15.02
14.66 – 15.32
+11.1% YoY
|
17.92
17.49 – 18.27
+19.3% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | JP Morgan | Neutral | Neutral | Maintain |
| 2026-05-01 | Wells Fargo | Overweight | Overweight | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 1/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 1/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 1/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 1/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | B- | 2/5 | 4/5 | 1/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group - 23-1945930 | 35.84M | 12.72% | — | 471.1K | 34.65M | 1.19M | IA | Pennsylvania | 2022-02-09 | ↗ |
| 2 | Wellington Management Company, LLP | 34.74M | 10.21% | — | 9.34M | — | — | IA | Massachusetts | 2014-07-10 | ↗ |
| 3 | 04-2683227 | 32.99M | 9.66% | — | 8.00M | — | — | IA | Massachusetts | 2014-02-14 | ↗ |
| 4 | (1) BlackRock, Inc. | 28.95M | 10.60% | 26.07M | — | 28.95M | — | HC | Delaware | 2022-09-08 | ↗ |
| 5 | STATE STREET CORPORATION | 21.38M | 7.59% | — | 19.46M | — | 21.35M | HC | — | 2022-02-10 | ↗ |
| 6 | 752403190 | 17.88M | 5.68% | 4.57M | 13.30M | 17.88M | — | IA | A Delaware limited liability company | 2018-02-12 | ↗ |
| 7 | Wellington Management Company LLP | 17.81M | 5.73% | — | 4.23M | — | — | IA | Delaware | 2018-08-10 | ↗ |
| 8 | 52-0556948 | 15.03M | 5.30% | 5.98M | — | 15.03M | — | IA | Maryland | 2022-02-14 | ↗ |
| 9 | Macquarie Bank Limited | 12.14M | 4.13% | — | — | — | — | CO | — | 2021-02-12 | ↗ |
| 10 | Macquarie Group Limited | 12.14M | 4.13% | — | — | — | — | HC | — | 2021-02-12 | ↗ |
| 11 | Macquarie Investment Management Business Trust | 12.05M | 4.11% | 11.66M | — | 11.66M | — | IA | — | 2021-02-12 | ↗ |
| 12 | Macquarie Investment Management Holdings Inc | 12.05M | 4.11% | 11.66M | — | 11.66M | — | HC | — | 2021-02-12 | ↗ |
| 13 | Cardinal Health, Inc. | 10.00M | 5.80% | 10.00M | — | 10.00M | — | CO | Ohio | 2017-03-13 | ↗ |
| 14 | Wellington Group Holdings LLP | 9.06M | 3.04% | — | 1.48M | — | — | HC | Delaware | 2019-02-12 | ↗ |
| 15 | Wellington Investment Advisors Holdings LLP | 9.06M | 3.04% | — | 1.48M | — | — | HC | Delaware | 2019-02-12 | ↗ |
| 16 | Wellington Management Group LLP | 9.06M | 3.04% | — | 1.48M | — | — | HC | Massachusetts | 2019-02-12 | ↗ |
| 17 | Macquarie Investment Management Australia Limited | 82.1K | 0.02% | 82.1K | — | 82.1K | — | CO | — | 2021-02-12 | ↗ |
| 18 | Macquarie Investment Management Austria Kapitalanlage AG | 13.7K | 0.00% | 13.7K | — | 13.7K | — | CO | Vienna, Austria | 2020-02-13 | ↗ |
| 19 | Macquarie Capital (USA) Inc. | 6.7K | 0.00% | 6.7K | — | 6.7K | — | CO | Sydney, New South Wales, Australia | 2020-02-13 | ↗ |
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 31.44M +617.8K (+2.0%) | 6.46B +1.6B (+33.5%) | 13.32% +0.426 pp | 0.09% +0.021 pp | USD75.73 +171.4% | 84 qtrs — |
| 2 | BLACKROCK, INC. | 28.64M -2.8M (-9.0%) | 5.89B +947.2M (+19.2%) | 12.14% -1.029 pp | 0.10% +0.013 pp | USD111.92 +83.6% | 6 qtrs — |
| 3 | STATE STREET CORP | 12.51M +221.5K (+1.8%) | 2.57B +642.0M (+33.3%) | 5.30% +0.159 pp | 0.09% +0.019 pp | USD57.31 +258.6% | 51 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 6.53M +43.9K (+0.7%) | 1.34B +322.8M (+31.8%) | 2.77% +0.053 pp | 0.08% +0.018 pp | USD68.90 +198.3% | 78 qtrs — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 5.17M -637.4K (-11.0%) | 1.06B +150.7M (+16.5%) | 2.19% -0.239 pp | 0.19% +0.027 pp | USD148.89 +38.0% | 81 qtrs — |
| 6 | MORGAN STANLEY | 5.12M -107.6K (-2.1%) | 1.05B +231.8M (+28.2%) | 2.17% -0.018 pp | 0.06% +0.013 pp | USD75.67 +171.6% | 51 qtrs — |
| 7 | FMR LLC | 4.60M -819.0K (-15.1%) | 945.52M +94.8M (+11.1%) | 1.95% -0.318 pp | 0.05% +0.004 pp | USD103.19 +99.1% | 70 qtrs — |
| 8 | WCM INVESTMENT MANAGEMENT, LLC | 4.03M +4.0M (+100.0%) | 835.61M +835.6M (+100.0%) | 1.71% +1.709 pp | 1.72% +1.721 pp | USD205.50 +0.0% | 1 qtrs NEW |
| 9 | NORGES BANK | 3.85M +3.8M (+100.0%) | 790.34M +790.3M (+100.0%) | 1.63% +1.630 pp | 0.08% +0.085 pp | USD205.50 +0.0% | 1 qtrs NEW |
| 10 | BANK OF AMERICA CORP /DE/ | 3.29M -304.0K (-8.5%) | 675.83M +111.9M (+19.8%) | 1.39% -0.110 pp | 0.05% +0.011 pp | USD98.44 +108.8% | 52 qtrs — |
| 11 | NORTHERN TRUST CORP | 2.86M -70.8K (-2.4%) | 586.77M +127.5M (+27.8%) | 1.21% -0.014 pp | 0.07% +0.016 pp | USD66.01 +211.3% | 51 qtrs — |
| 12 | VICTORY CAPITAL MANAGEMENT INC | 2.70M +414.1K (+18.1%) | 554.48M +202.3M (+57.4%) | 1.14% +0.188 pp | 0.31% +0.107 pp | USD142.35 +44.4% | 44 qtrs — |
| 13 | JPMORGAN CHASE & CO | 2.63M -267.9K (-9.2%) | 540.63M +85.6M (+18.8%) | 1.11% -0.098 pp | 0.03% +0.007 pp | USD111.17 +84.9% | 51 qtrs — |
| 14 | INVESCO LTD. | 2.58M -898.5K (-25.8%) | 531.16M -15.6M (-2.8%) | 1.10% -0.362 pp | 0.08% -0.005 pp | USD83.27 +146.8% | 57 qtrs — |
| 15 | UBS ASSET MANAGEMENT AMERICAS INC | 2.31M -201.2K (-8.0%) | 475.49M +80.7M (+20.5%) | 0.98% -0.072 pp | 0.10% +0.015 pp | USD83.24 +146.9% | 90 qtrs — |
| 16 | LEGAL & GENERAL GROUP PLC | 2.13M -12.1K (-0.6%) | 436.98M +101.3M (+30.2%) | 0.90% +0.006 pp | 0.10% +0.022 pp | USD59.86 +243.3% | 75 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 2.05M +74.1K (+3.7%) | 421.63M +111.2M (+35.8%) | 0.87% +0.042 pp | 0.05% +0.014 pp | USD109.22 +88.2% | 73 qtrs — |
| 18 | CITADEL ADVISORS LLC | 1.88M +934.8K (+99.2%) | 385.66M +237.8M (+160.8%) | 0.80% +0.401 pp | 0.06% +0.035 pp | USD158.19 +29.9% | 52 qtrs — |
| 19 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.87M -101.4K (-5.2%) | 383.52M +74.7M (+24.2%) | 0.79% -0.033 pp | 0.04% +0.008 pp | USD78.64 +161.3% | 75 qtrs — |
| 20 | BNP PARIBAS ARBITRAGE, SNC | 1.59M -368.4K (-18.8%) | 326.40M +19.3M (+6.3%) | 0.67% -0.146 pp | 0.15% -0.016 pp | USD124.82 +64.6% | 51 qtrs — |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.56M +5.2K (+0.3%) | 320.08M +76.4M (+31.4%) | 0.66% +0.011 pp | 0.05% +0.011 pp | USD62.67 +227.9% | 100 qtrs — |
| 22 | VOYA INVESTMENT MANAGEMENT LLC | 1.44M +614.9K (+74.8%) | 295.23M +166.2M (+128.9%) | 0.61% +0.265 pp | 0.29% +0.162 pp | USD164.79 +24.7% | 51 qtrs — |
| 23 | ACADIAN ASSET MANAGEMENT LLC | 1.43M +400.7K (+38.9%) | 293.86M +132.3M (+81.9%) | 0.61% +0.175 pp | 0.48% +0.201 pp | USD149.72 +37.3% | 50 qtrs — |
| 24 | BANK OF NEW YORK MELLON CORP | 1.39M -47.1K (-3.3%) | 286.43M +60.3M (+26.6%) | 0.59% -0.012 pp | 0.05% +0.007 pp | USD53.99 +280.6% | 66 qtrs — |
| 25 | AQR CAPITAL MANAGEMENT LLC | 1.35M +25.3K (+1.9%) | 278.20M +71.3M (+34.5%) | 0.57% +0.018 pp | 0.15% +0.013 pp | USD87.27 +135.5% | 92 qtrs — |
| 26 | PACER ADVISORS, INC. | 1.30M +444.0K (+52.0%) | 266.56M +132.6M (+99.1%) | 0.55% +0.193 pp | 0.68% +0.344 pp | USD179.98 +14.2% | 44 qtrs — |
| 27 | BARCLAYS PLC | 1.21M +501.2K (+70.8%) | 248.37M +170.2M (+217.7%) | 0.51% +0.216 pp | 0.06% +0.040 pp | USD141.95 +44.8% | 51 qtrs — |
| 28 | DIMENSIONAL FUND ADVISORS LP | 1.18M -71.2K (-5.7%) | 241.54M +45.9M (+23.5%) | 0.50% -0.024 pp | 0.05% +0.009 pp | USD57.62 +256.6% | 51 qtrs — |
| 29 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.05M -326.9K (-23.8%) | 215.19M -489.8K (-0.2%) | 0.44% -0.131 pp | 0.22% -0.004 pp | USD103.08 +99.4% | 13 qtrs — |
| 30 | PROSHARE ADVISORS LLC | 1.04M -66.4K (-6.0%) | 214.14M +40.2M (+23.1%) | 0.44% -0.022 pp | 0.38% +0.014 pp | USD62.28 +230.0% | 77 qtrs — |
| 31 | KBC GROUP NV | 1.02M +5.6K (+0.6%) | 210.01M +50.5M (+31.6%) | 0.43% +0.008 pp | 0.48% +0.096 pp | USD105.13 +95.5% | 68 qtrs — |
| 32 | MAN GROUP PLC | 1.02M -584.6K (-36.4%) | 209.77M -42.2M (-16.7%) | 0.43% -0.239 pp | 0.36% -0.082 pp | USD113.17 +81.6% | 32 qtrs — |
| 33 | DEUTSCHE BANK AG\ | 993.2K +6.8K (+0.7%) | 204.11M +49.3M (+31.8%) | 0.42% +0.008 pp | 0.07% +0.015 pp | USD88.77 +131.5% | 50 qtrs — |
| 34 | HOLOCENE ADVISORS, LP | 989.5K -936.7K (-48.6%) | 203.34M -99.0M (-32.7%) | 0.42% -0.387 pp | 0.43% -0.262 pp | USD147.90 +38.9% | 11 qtrs — |
| 35 | UBS GROUP AG | 968.8K -35.5K (-3.5%) | 199.10M +41.5M (+26.3%) | 0.41% -0.010 pp | 0.03% +0.008 pp | USD97.62 +110.5% | 45 qtrs — |
| 36 | MARSHALL WACE, LLP | 951.3K +884.6K (+1,328.1%) | 195.48M +185.0M (+1,769.7%) | 0.40% +0.375 pp | 0.18% +0.167 pp | USD199.77 +2.9% | 31 qtrs — |
| 37 | NUVEEN, LLC | 944.9K +21.8K (+2.4%) | 194.17M +49.3M (+34.0%) | 0.40% +0.014 pp | 0.05% +0.013 pp | USD142.78 +43.9% | 4 qtrs — |
| 38 | ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. | 891.3K -45.5K (-4.9%) | 183.16M +36.1M (+24.6%) | 0.38% -0.014 pp | 0.26% +0.048 pp | USD78.81 +160.8% | 68 qtrs — |
| 39 | ENVESTNET ASSET MANAGEMENT INC | 883.4K +132.7K (+17.7%) | 181.53M +63.7M (+54.1%) | 0.37% +0.060 pp | 0.05% +0.020 pp | USD106.90 +92.2% | 51 qtrs — |
| 40 | AMERIPRISE FINANCIAL INC | 818.6K -636.6K (-43.7%) | 168.22M -60.3M (-26.4%) | 0.35% -0.262 pp | 0.04% -0.015 pp | USD101.87 +101.7% | 56 qtrs — |
| 41 | TWO SIGMA INVESTMENTS, LP | 805.8K +652.4K (+425.2%) | 165.59M +141.5M (+587.6%) | 0.34% +0.277 pp | 0.23% +0.198 pp | USD186.31 +10.3% | 18 qtrs — |
| 42 | BRANDES INVESTMENT PARTNERS, LP | 781.9K -208.7K (-21.1%) | 160.68M +5.2M (+3.3%) | 0.33% -0.083 pp | 1.22% -0.024 pp | USD68.22 +201.2% | 35 qtrs — |
| 43 | RENAISSANCE TECHNOLOGIES LLC | 773.8K +81.5K (+11.8%) | 159.02M +50.4M (+46.3%) | 0.33% +0.038 pp | 0.25% +0.103 pp | USD112.03 +83.4% | 33 qtrs — |
| 44 | AUSTRALIANSUPER PTY LTD | 765.0K +84.8K (+12.5%) | 157.21M +50.5M (+47.3%) | 0.32% +0.040 pp | 0.73% +0.240 pp | USD165.25 +24.4% | 3 qtrs — |
| 45 | FEDERATED HERMES, INC. | 763.6K -197.3K (-20.5%) | 156.91M +6.1M (+4.0%) | 0.32% -0.079 pp | 0.26% -0.004 pp | USD122.22 +68.1% | 54 qtrs — |
| 46 | AMUNDI | 736.4K +55.8K (+8.2%) | 151.34M +45.7M (+43.3%) | 0.31% +0.027 pp | 0.04% +0.007 pp | USD72.74 +182.5% | 19 qtrs — |
| 47 | SG AMERICAS SECURITIES, LLC | 727.5K +709.0K (+3,829.1%) | 149.50M +146.6M (+5,044.7%) | 0.31% +0.301 pp | 0.19% +0.181 pp | USD203.39 +1.0% | 51 qtrs — |
| 48 | WELLS FARGO & COMPANY/MN | 722.4K -9.9K (-1.4%) | 148.46M +33.5M (+29.1%) | 0.31% 0.000 pp | 0.03% +0.005 pp | USD85.07 +141.6% | 57 qtrs — |
| 49 | PRUDENTIAL FINANCIAL INC | 710.1K +496.3K (+232.1%) | 145.92M +112.4M (+334.9%) | 0.30% +0.211 pp | 0.18% +0.136 pp | USD190.18 +8.1% | 85 qtrs — |
| 50 | ROYAL BANK OF CANADA | 707.3K +113.6K (+19.1%) | 145.35M +52.2M (+56.0%) | 0.30% +0.051 pp | 0.02% +0.008 pp | USD112.68 +82.4% | 51 qtrs — |
| 51 | BANK OF NOVA SCOTIA | 692.6K +299.1K (+76.0%) | 142.33M +80.6M (+130.5%) | 0.29% +0.129 pp | 0.21% +0.102 pp | USD168.25 +22.1% | 52 qtrs — |
| 52 | SEI INVESTMENTS CO | 686.4K +198.7K (+40.7%) | 141.05M +64.5M (+84.3%) | 0.29% +0.087 pp | 0.14% +0.057 pp | USD123.03 +67.0% | 45 qtrs — |
| 53 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 651.9K -115.8K (-15.1%) | 133.96M +13.5M (+11.2%) | 0.28% -0.045 pp | 0.47% +0.066 pp | USD106.66 +92.7% | 26 qtrs — |
| 54 | NORDEA INVESTMENT MANAGEMENT AB | 645.4K +494.7K (+328.3%) | 133.74M +110.2M (+467.5%) | 0.27% +0.210 pp | 0.11% +0.094 pp | USD192.69 +6.6% | 88 qtrs — |
| 55 | SWISS NATIONAL BANK | 650.4K -37.6K (-5.5%) | 133.66M +25.7M (+23.8%) | 0.28% -0.012 pp | 0.08% +0.017 pp | USD73.42 +179.9% | 51 qtrs — |
| 56 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 644.6K -146.7K (-18.5%) | 132.46M +8.3M (+6.7%) | 0.27% -0.058 pp | 0.08% +0.001 pp | USD82.12 +150.2% | 58 qtrs — |
| 57 | SCHRODER INVESTMENT MANAGEMENT GROUP | 614.4K +52.7K (+9.4%) | 127.30M +40.5M (+46.6%) | 0.26% +0.025 pp | 0.10% +0.030 pp | USD157.90 +30.1% | 51 qtrs — |
| 58 | HSBC HOLDINGS PLC | 612.5K -103.1K (-14.4%) | 126.04M +13.6M (+12.1%) | 0.26% -0.040 pp | 0.06% +0.002 pp | USD116.48 +76.4% | 56 qtrs — |
| 59 | RHUMBLINE ADVISERS | 606.6K -12.6K (-2.0%) | 124.65M +27.5M (+28.3%) | 0.26% -0.002 pp | 0.10% +0.023 pp | USD68.35 +200.7% | 52 qtrs — |
| 60 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 603.6K -26.1K (-4.2%) | 124.03M +25.2M (+25.5%) | 0.26% -0.008 pp | 0.07% +0.016 pp | USD53.45 +284.5% | 59 qtrs — |
| 61 | FRANKLIN RESOURCES INC | 585.1K +98.0K (+20.1%) | 120.23M +43.8M (+57.3%) | 0.25% +0.044 pp | 0.03% +0.010 pp | USD159.06 +29.2% | 51 qtrs — |
| 62 | RAYMOND JAMES FINANCIAL INC | 577.5K +44.1K (+8.3%) | 118.82M +35.1M (+41.9%) | 0.24% +0.022 pp | 0.04% +0.010 pp | USD132.00 +55.7% | 5 qtrs — |
| 63 | FARALLON CAPITAL MANAGEMENT LLC | 576.0K +323.0K (+127.7%) | 118.37M +78.7M (+198.1%) | 0.24% +0.138 pp | 0.56% +0.396 pp | USD181.04 +13.5% | 4 qtrs — |
| 64 | POINT72 ASSET MANAGEMENT, L.P. | 548.3K +424.3K (+342.2%) | 112.68M +93.2M (+478.9%) | 0.23% +0.180 pp | 0.13% +0.093 pp | USD184.51 +11.4% | 7 qtrs — |
| 65 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 529.9K +25.3K (+5.0%) | 109.00M +29.8M (+37.6%) | 0.22% +0.013 pp | 0.07% +0.017 pp | USD89.02 +130.8% | 58 qtrs — |
| 66 | SQUAREPOINT OPS LLC | 530.1K -578.3K (-52.2%) | 108.95M -65.0M (-37.4%) | 0.22% -0.239 pp | 0.12% -0.059 pp | USD149.05 +37.9% | 35 qtrs — |
| 67 | NATIXIS ADVISORS, L.P. | 521.3K +85.6K (+19.6%) | 107.12M +38.7M (+56.6%) | 0.22% +0.039 pp | 0.15% +0.052 pp | USD106.59 +92.8% | 57 qtrs — |
| 68 | D. E. SHAW & CO., INC. | 489.6K -122.4K (-20.0%) | 100.62M +4.6M (+4.7%) | 0.21% -0.049 pp | 0.06% +0.001 pp | USD113.94 +80.4% | 76 qtrs — |
| 69 | NATIONAL PENSION SERVICE | 485.0K -15.3K (-3.1%) | 99.67M +21.1M (+26.9%) | 0.21% -0.004 pp | 0.07% +0.013 pp | USD66.28 +210.0% | 46 qtrs — |
| 70 | CAPITAL INTERNATIONAL INVESTORS | 472.4K +472.4K (+100.0%) | 97.08M +97.1M (+100.0%) | 0.20% +0.200 pp | 0.02% +0.015 pp | USD205.50 +0.0% | 1 qtrs NEW |
| 71 | TWO SIGMA ADVISERS, LP | 469.3K +453.7K (+2,908.3%) | 96.44M +94.0M (+3,838.7%) | 0.20% +0.192 pp | 0.19% +0.183 pp | USD202.06 +1.7% | 50 qtrs — |
| 72 | JANE STREET GROUP, LLC | 452.2K +437.5K (+2,983.4%) | 92.92M +90.6M (+3,936.9%) | 0.19% +0.186 pp | 0.01% +0.014 pp | USD202.27 +1.6% | 48 qtrs — |
| 73 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 450.6K +13.1K (+3.0%) | 92.60M +23.9M (+34.8%) | 0.19% +0.008 pp | 0.01% +0.003 pp | USD123.85 +65.9% | 51 qtrs — |
| 74 | NATIONAL BANK OF CANADA /FI/ | 433.8K +95.9K (+28.4%) | 89.14M +36.1M (+68.1%) | 0.18% +0.042 pp | 0.08% +0.028 pp | USD142.71 +44.0% | 17 qtrs — |
| 75 | CIBC PRIVATE WEALTH GROUP, LLC | 431.8K -10.0K (-2.3%) | 88.73M +19.4M (+28.0%) | 0.18% -0.002 pp | 0.15% +0.031 pp | USD99.63 +106.3% | 40 qtrs — |
| 76 | ING GROEP NV | 430.2K -87.9K (-17.0%) | 88.41M +7.1M (+8.7%) | 0.18% -0.035 pp | 0.53% +0.093 pp | USD153.68 +33.7% | 51 qtrs — |
| 77 | LPL FINANCIAL LLC | 424.7K +1.0K (+0.2%) | 87.28M +20.8M (+31.2%) | 0.18% +0.003 pp | 0.02% +0.005 pp | USD117.45 +75.0% | 51 qtrs — |
| 78 | SWEDBANK AB | 415.7K -12.8K (-3.0%) | 85.43M +18.2M (+27.0%) | 0.18% -0.003 pp | 0.08% +0.015 pp | USD60.14 +241.7% | 20 qtrs — |
| 79 | RUSSELL INVESTMENTS GROUP, LTD. | 408.8K -86.4K (-17.4%) | 84.13M +6.5M (+8.4%) | 0.17% -0.034 pp | 0.09% +0.004 pp | USD83.44 +146.3% | 37 qtrs — |
| 80 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 408.7K -14.1K (-3.3%) | 83.99M +17.6M (+26.6%) | 0.17% -0.004 pp | 0.58% +0.138 pp | USD163.00 +26.1% | 60 qtrs — |
| 81 | FRED ALGER MANAGEMENT, LLC | 404.7K -68.0K (-14.4%) | 83.16M +9.0M (+12.1%) | 0.17% -0.026 pp | 0.33% +0.037 pp | USD155.95 +31.8% | 14 qtrs — |
| 82 | MILLENNIUM MANAGEMENT LLC | 404.4K -1.6M (-79.6%) | 83.11M -228.4M (-73.3%) | 0.17% -0.659 pp | 0.03% -0.098 pp | USD126.77 +62.1% | 34 qtrs — |
| 83 | CITIGROUP INC | 395.8K -5.9K (-1.5%) | 81.34M +18.3M (+29.0%) | 0.17% 0.000 pp | 0.04% +0.008 pp | USD98.55 +108.5% | 108 qtrs — |
| 84 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 380.4K -39.1K (-9.3%) | 78.18M +12.3M (+18.7%) | 0.16% -0.014 pp | 0.08% +0.011 pp | USD54.88 +274.5% | 52 qtrs — |
| 85 | RETIREMENT SYSTEMS OF ALABAMA | 377.9K -395.0 (-0.1%) | 77.66M +18.3M (+30.8%) | 0.16% +0.002 pp | 0.25% +0.055 pp | USD56.72 +262.3% | 52 qtrs — |
| 86 | TD ASSET MANAGEMENT INC | 374.5K +22.0K (+6.3%) | 76.97M +21.6M (+39.1%) | 0.16% +0.011 pp | 0.06% +0.017 pp | USD89.76 +128.9% | 51 qtrs — |
| 87 | ARTEMIS INVESTMENT MANAGEMENT LLP | 344.2K +50.5K (+17.2%) | 70.74M +24.6M (+53.4%) | 0.15% +0.023 pp | 0.85% +0.281 pp | USD160.88 +27.7% | 4 qtrs — |
| 88 | DELTA ACCUMULATION, LLC | 336.8K +153.7K (+83.9%) | 69.21M +49.0M (+242.0%) | 0.14% +0.066 pp | 2.55% +1.284 pp | USD180.37 +13.9% | 12 qtrs — |
| 89 | WOODLINE PARTNERS LP | 328.3K +328.3K (+100.0%) | 67.47M +67.5M (+100.0%) | 0.14% +0.139 pp | 0.26% +0.261 pp | USD205.50 +0.0% | 5 qtrs — |
| 90 | NEW YORK STATE COMMON RETIREMENT FUND | 327.1K +— (+0.0%) | 67.23M +15.9M (+30.9%) | 0.14% +0.002 pp | 0.09% +0.023 pp | USD53.47 +284.3% | 103 qtrs — |
| 91 | COLONY GROUP, LLC | 328.4K -40.6K (-11.0%) | 67.22M +26.0M (+63.2%) | 0.14% -0.015 pp | 0.08% +0.010 pp | USD154.75 +32.8% | 9 qtrs — |
| 92 | CBOE VEST FINANCIAL, LLC | 319.7K -45.7K (-12.5%) | 65.70M +8.3M (+14.5%) | 0.14% -0.017 pp | 0.83% +0.084 pp | USD88.87 +131.2% | 21 qtrs — |
| 93 | NOMURA ASSET MANAGEMENT CO LTD | 315.9K -25.0K (-7.3%) | 64.91M +11.4M (+21.3%) | 0.13% -0.009 pp | 0.16% +0.025 pp | USD72.89 +181.9% | 76 qtrs — |
| 94 | DEKABANK DEUTSCHE GIROZENTRALE | 570.5K +— (+0.0%) | 64.40M -23.6M (-26.8%) | 0.24% +0.003 pp | 0.11% -0.037 pp | USD85.25 +141.1% | 65 qtrs — |
| 95 | ALLIANCEBERNSTEIN L.P. | 311.6K +32.0K (+11.4%) | 64.04M +20.2M (+45.9%) | 0.13% +0.015 pp | 0.02% +0.006 pp | USD81.41 +152.4% | 61 qtrs — |
| 96 | ZURICH INSURANCE GROUP LTD/FI | 295.3K +276.5K (+1,470.6%) | 60.68M +57.7M (+1,956.3%) | 0.13% +0.117 pp | 0.42% +0.400 pp | USD201.14 +2.2% | 15 qtrs — |
| 97 | PRINCIPAL FINANCIAL GROUP INC | 287.5K +11.1K (+4.0%) | 59.09M +15.7M (+36.2%) | 0.12% +0.006 pp | 0.03% +0.008 pp | USD69.13 +197.3% | 81 qtrs — |
| 98 | ZACKS INVESTMENT MANAGEMENT | 286.3K +9.9K (+3.6%) | 58.83M +15.5M (+35.6%) | 0.12% +0.006 pp | 0.46% +0.117 pp | USD135.02 +52.2% | 9 qtrs — |
| 99 | — | 268.1K +268.1K (+100.0%) | 55.56M +55.6M (+100.0%) | 0.11% +0.114 pp | 0.16% +0.158 pp | USD205.50 +0.0% | 1 qtrs NEW |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Hall Patricia Hemingway | Director | A-Award | A | Common Shares | 381 | 207.83 | 79.2K | 28,645 | D | ↗ |
| 2026-02-27 | Greene Michelle D. | Officer | S-Sale | D | Common Shares | 100 | 228.55 | 22.9K | 14,876 | D | ↗ |
| 2026-02-18 | Alt Aaron E | Officer | S-Sale | D | Common Shares | 2,328 | 225.50 | 525.0K | 26,408 | D | ↗ |
| 2026-02-15 | Alt Aaron E | Officer | F-InKind | D | Common Shares | 1,914 | 220.79 | 422.6K | 28,736 | D | ↗ |
| 2026-02-06 | Hall Patricia Hemingway | Director | S-Sale | D | Common Shares | 4,000 | 229.72 | 918.9K | 28,264 | D | ↗ |
| 2026-01-15 | Pitteroff Valerie Christine | Officer | A-Award | A | Common Shares | 3,982 | 213.26 | 849.2K | 8,022 | D | ↗ |
| 2025-12-29 | Pitteroff Valerie Christine | Officer | — | — | Common Shares | 0 | 0.00 | — | 4,040 | D | ↗ |
| 2025-12-01 | WEITZMAN DEBORAH | Officer | F-InKind | D | Common Shares | 551 | 212.26 | 117.0K | 52,877 | D | ↗ |
| 2025-12-01 | Snow Ola M | Officer | F-InKind | D | Common Shares | 320 | 212.26 | 67.9K | 15,111 | D | ↗ |
| 2025-12-01 | Scherer Mary C. | Officer | F-InKind | D | Common Shares | 61 | 212.26 | 12.9K | 3,495 | D | ↗ |
| 2025-12-01 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 422 | 212.26 | 89.6K | 34,427 | D | ↗ |
| 2025-12-01 | Mason Stephen M | Officer | F-InKind | D | Common Shares | 595 | 212.26 | 126.3K | 25,490 | D | ↗ |
| 2025-11-05 | Ramakrishna Sudhakar | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 2,116 | D | ↗ |
| 2025-11-05 | Musslewhite Robert W | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 2,116 | D | ↗ |
| 2025-11-05 | MUNDKUR CHRISTINE | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 7,536 | D | ↗ |
| 2025-11-05 | Killefer Nancy | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 27,624 | D | ↗ |
| 2025-11-05 | KENNY GREGORY B | Director | A-Award | A | Common Shares | 1,702 | 0.00 | — | 64,194 | D | ↗ |
| 2025-11-05 | JOHRI AKHIL | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 22,868 | D | ↗ |
| 2025-11-05 | Hall Patricia Hemingway | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 32,264 | D | ↗ |
| 2025-11-05 | Evans David C | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 15,373 | D | ↗ |
| 2025-11-05 | Edison Sheri H. | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 14,848 | D | ↗ |
| 2025-11-05 | Brennan Michelle | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 8,086 | D | ↗ |
| 2025-11-05 | Azelby Robert | Director | A-Award | A | Common Shares | 1,067 | 0.00 | — | 4,085 | D | ↗ |
| 2025-08-20 | WEITZMAN DEBORAH | Officer | S-Sale | D | Common Shares | 21,367 | 150.53 | 3.22M | 53,428 | D | ↗ |
| 2025-08-20 | Hollar Jason M. | Officer | S-Sale | D | Common Shares | 12,944 | 149.40 | 1.93M | 222,957 | D | ↗ |
| 2025-08-19 | Snow Ola M | Officer | S-Sale | D | Common Shares | 23,700 | 148.86 | 3.53M | 19,882 | D | ↗ |
| 2025-08-19 | Scherer Mary C. | Officer | S-Sale | D | Common Shares | 6,766 | 149.25 | 1.01M | 3,556 | D | ↗ |
| 2025-08-19 | Mayer Jessica L | Officer | S-Sale | D | Common Shares | 33,333 | 148.91 | 4.96M | 48,857 | D | ↗ |
| 2025-08-19 | Mason Stephen M | Officer | S-Sale | D | Common Shares | 4,167 | 149.39 | 622.5K | 26,085 | D | ↗ |
| 2025-08-19 | Hollar Jason M. | Officer | S-Sale | D | Common Shares | 94,735 | 148.92 | 14.11M | 242,214 | D | ↗ |
| 2025-08-19 | Greene Michelle D. | Officer | S-Sale | D | Common Shares | 11,994 | 148.76 | 1.78M | 16,482 | D | ↗ |
| 2025-08-19 | Alt Aaron E | Officer | S-Sale | D | Common Shares | 34,455 | 148.61 | 5.12M | 44,438 | D | ↗ |
| 2025-08-15 | WEITZMAN DEBORAH | Officer | F-InKind | D | Common Shares | 24,128 | 150.22 | 3.62M | 74,795 | D | ↗ |
| 2025-08-15 | Snow Ola M | Officer | A-Award | A | Common Shares | 6,417 | 0.00 | — | 61,768 | D | ↗ |
| 2025-08-15 | Scherer Mary C. | Officer | F-InKind | D | Common Shares | 2,572 | 150.22 | 386.4K | 10,322 | D | ↗ |
| 2025-08-15 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 27,927 | 150.22 | 4.20M | 86,535 | D | ↗ |
| 2025-08-15 | Mason Stephen M | Officer | F-InKind | D | Common Shares | 30,811 | 150.22 | 4.63M | 67,660 | D | ↗ |
| 2025-08-15 | Hollar Jason M. | Officer | F-InKind | D | Common Shares | 136,407 | 150.22 | 20.49M | 343,606 | D | ↗ |
| 2025-08-15 | Greene Michelle D. | Officer | A-Award | A | Common Shares | 3,476 | 0.00 | — | 38,444 | D | ↗ |
| 2025-08-15 | Alt Aaron E | Officer | F-InKind | D | Common Shares | 34,866 | 150.22 | 5.24M | 78,893 | D | ↗ |
| 2025-08-12 | WEITZMAN DEBORAH | Officer | A-Award | A | Common Shares | 39,100 | 0.00 | — | 88,229 | D | ↗ |
| 2025-08-12 | Snow Ola M | Officer | A-Award | A | Common Shares | 31,813 | 0.00 | — | 55,351 | D | ↗ |
| 2025-08-12 | Scherer Mary C. | Officer | A-Award | A | Common Shares | 3,029 | 0.00 | — | 11,691 | D | ↗ |
| 2025-08-12 | Mayer Jessica L | Officer | A-Award | A | Common Shares | 49,994 | 0.00 | — | 105,104 | D | ↗ |
| 2025-08-12 | Mason Stephen M | Officer | A-Award | A | Common Shares | 54,537 | 0.00 | — | 89,514 | D | ↗ |
| 2025-08-12 | Hollar Jason M. | Officer | A-Award | A | Common Shares | 245,420 | 0.00 | — | 437,235 | D | ↗ |
| 2025-08-12 | Greene Michelle D. | Officer | A-Award | A | Common Shares | 16,362 | 0.00 | — | 34,968 | D | ↗ |
| 2025-08-12 | Alt Aaron E | Officer | A-Award | A | Common Shares | 67,448 | 0.00 | — | 102,396 | D | ↗ |
| 2025-06-30 | Snow Ola M | Officer | F-InKind | D | Common Shares | 3,623 | 167.18 | 605.7K | 23,538 | D | ↗ |
| 2025-06-30 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 5,176 | 167.18 | 865.3K | 55,110 | D | ↗ |
| 2025-06-30 | Mason Stephen M | Officer | F-InKind | D | Common Shares | 5,694 | 167.18 | 951.9K | 34,977 | D | ↗ |
| 2025-06-30 | Hollar Jason M. | Officer | F-InKind | D | Common Shares | 5,821 | 167.18 | 973.2K | 191,815 | D | ↗ |
| 2025-03-15 | Ramakrishna Sudhakar | Director | A-Award | A | Common Shares | 1,049 | 0.00 | — | 1,049 | D | ↗ |
| 2025-03-15 | Musslewhite Robert W | Director | A-Award | A | Common Shares | 1,049 | 0.00 | — | 1,049 | D | ↗ |
| 2025-03-07 | Ramakrishna Sudhakar | Director | — | — | Common Shares | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-03-07 | Musslewhite Robert W | Director | — | — | Common Shares | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-02-15 | Greene Michelle D. | Officer | F-InKind | D | Common Shares | 636 | 126.21 | 80.3K | 18,606 | D | ↗ |
| 2025-02-15 | Alt Aaron E | Officer | F-InKind | D | Common Shares | 1,919 | 126.21 | 242.2K | 34,948 | D | ↗ |
| 2024-12-02 | WEITZMAN DEBORAH | Officer | F-InKind | D | Common Shares | 632 | 122.24 | 77.3K | 49,129 | D | ↗ |
| 2024-12-02 | Snow Ola M | Officer | F-InKind | D | Common Shares | 355 | 122.24 | 43.4K | 27,161 | D | ↗ |
| 2024-12-02 | Scherer Mary C. | Officer | F-InKind | D | Common Shares | 90 | 122.24 | 11.0K | 8,662 | D | ↗ |
| 2024-12-02 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 676 | 122.24 | 82.6K | 60,286 | D | ↗ |
| 2024-11-15 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 5,186 | 121.29 | 629.0K | 70,785 | D | ↗ |
| 2024-11-14 | Scherer Mary C. | Officer | S-Sale | D | Common Shares | 3,504 | 123.55 | 432.9K | 8,752 | D | ↗ |
| 2024-11-06 | MUNDKUR CHRISTINE | Director | A-Award | A | Common Shares | 1,730 | 0.00 | — | 6,469 | D | ↗ |
| 2024-11-06 | Killefer Nancy | Director | A-Award | A | Common Shares | 1,730 | 0.00 | — | 26,557 | D | ↗ |
| 2024-11-06 | KENNY GREGORY B | Director | A-Award | A | Common Shares | 2,812 | 0.00 | — | 62,492 | D | ↗ |
| 2024-11-06 | JOHRI AKHIL | Director | A-Award | A | Common Shares | 1,730 | 0.00 | — | 21,801 | D | ↗ |
| 2024-11-06 | Hall Patricia Hemingway | Director | A-Award | A | Common Shares | 1,730 | 0.00 | — | 31,197 | D | ↗ |
| 2024-11-06 | Evans David C | Director | A-Award | A | Common Shares | 1,730 | 0.00 | — | 14,306 | D | ↗ |
| 2024-11-06 | Edison Sheri H. | Director | A-Award | A | Common Shares | 1,730 | 0.00 | — | 13,781 | D | ↗ |
| 2024-11-06 | Brennan Michelle | Director | A-Award | A | Common Shares | 1,730 | 0.00 | — | 7,019 | D | ↗ |
| 2024-11-06 | Azelby Robert | Director | A-Award | A | Common Shares | 1,730 | 0.00 | — | 3,018 | D | ↗ |
| 2024-08-21 | Mayer Jessica L | Officer | S-Sale | D | Common Shares | 16,573 | 109.39 | 1.81M | 75,971 | — | ↗ |
| 2024-08-19 | Snow Ola M | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,980 | 83.19 | 497.5K | 0 | — | ↗ |
| 2024-08-19 | Mason Stephen M | Officer | M-Exempt | A | Common Shares | 8,971 | 83.19 | 746.3K | 87,669 | — | ↗ |
| 2024-08-19 | Hollar Jason M. | Officer | S-Sale | D | Common Shares | 46,455 | 109.02 | 5.06M | 197,636 | — | ↗ |
| 2024-08-19 | Greene Michelle D. | Officer | S-Sale | D | Common Shares | 4,000 | 108.85 | 435.4K | 19,242 | — | ↗ |
| 2024-08-19 | Alt Aaron E | Officer | S-Sale | D | Common Shares | 2,323 | 108.91 | 253.0K | 36,867 | — | ↗ |
| 2024-08-16 | WEITZMAN DEBORAH | Officer | F-InKind | D | Common Shares | 2,341 | 107.91 | 252.6K | 49,761 | — | ↗ |
| 2024-08-16 | Snow Ola M | Officer | G-Gift | D | Common Shares | 943 | 0.00 | — | 44,496 | — | ↗ |
| 2024-08-16 | Scherer Mary C. | Officer | F-InKind | D | Common Shares | 249 | 107.91 | 26.9K | 12,256 | — | ↗ |
| 2024-08-16 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 1,985 | 107.91 | 214.2K | 92,544 | — | ↗ |
| 2024-08-16 | Mason Stephen M | Officer | F-InKind | D | Common Shares | 1,985 | 107.91 | 214.2K | 72,708 | — | ↗ |
| 2024-08-16 | Hollar Jason M. | Officer | S-Sale | D | Common Shares | 26,716 | 108.87 | 2.91M | 244,091 | — | ↗ |
| 2024-08-16 | Greene Michelle D. | Officer | F-InKind | D | Common Shares | 1,493 | 107.91 | 161.1K | 23,242 | — | ↗ |
| 2024-08-16 | Alt Aaron E | Officer | F-InKind | D | Common Shares | 2,481 | 107.91 | 267.7K | 39,190 | — | ↗ |
| 2024-08-15 | WEITZMAN DEBORAH | Officer | A-Award | A | Common Shares | 13,530 | 0.00 | — | 52,102 | — | ↗ |
| 2024-08-15 | Snow Ola M | Officer | F-InKind | D | Common Shares | 12,576 | 106.36 | 1.34M | 41,511 | — | ↗ |
| 2024-08-15 | Scherer Mary C. | Officer | F-InKind | D | Common Shares | 2,380 | 106.36 | 253.1K | 10,837 | — | ↗ |
| 2024-08-15 | Mayer Jessica L | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,534 | 66.43 | 367.6K | 0 | — | ↗ |
| 2024-08-15 | Mason Stephen M | Officer | A-Award | A | Common Shares | 12,047 | 0.00 | — | 74,693 | — | ↗ |
| 2024-08-15 | Hollar Jason M. | Officer | F-InKind | D | Common Shares | 30,275 | 106.36 | 3.22M | 230,494 | — | ↗ |
| 2024-08-15 | Greene Michelle D. | Officer | F-InKind | D | Common Shares | 2,355 | 106.36 | 250.5K | 19,916 | — | ↗ |
| 2024-08-15 | Alt Aaron E | Officer | A-Award | A | Common Shares | 14,271 | 0.00 | — | 41,671 | — | ↗ |
| 2024-08-13 | WEITZMAN DEBORAH | Officer | A-Award | A | Common Shares | 13,926 | 0.00 | — | 48,490 | — | ↗ |
| 2024-08-13 | Snow Ola M | Officer | A-Award | A | Common Shares | 29,245 | 0.00 | — | 54,087 | — | ↗ |
| 2024-08-13 | Scherer Mary C. | Officer | A-Award | A | Common Shares | 2,785 | 0.00 | — | 13,217 | — | ↗ |
| 2024-08-13 | Mayer Jessica L | Officer | A-Award | A | Common Shares | 41,780 | 0.00 | — | 111,068 | — | ↗ |
| 2024-08-13 | Mason Stephen M | Officer | A-Award | A | Common Shares | 45,958 | 0.00 | — | 83,313 | — | ↗ |
| 2024-08-13 | Hollar Jason M. | Officer | A-Award | A | Common Shares | 45,958 | 0.00 | — | 260,769 | — | ↗ |
| 2024-08-13 | Greene Michelle D. | Officer | A-Award | A | Common Shares | 2,785 | 0.00 | — | 22,271 | — | ↗ |
| 2024-03-15 | Greene Michelle D. | Officer | F-InKind | D | Common Shares | 664 | 109.93 | 73.0K | 19,486 | — | ↗ |
| 2024-03-15 | Azelby Robert | Director | A-Award | A | Common Shares | 1,288 | 0.00 | — | 1,288 | — | ↗ |
| 2024-03-01 | Azelby Robert | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-15 | Greene Michelle D. | Officer | F-InKind | D | Common Shares | 664 | 103.55 | 68.8K | 20,150 | — | ↗ |
| 2024-02-15 | Alt Aaron E | Officer | F-InKind | D | Common Shares | 1,919 | 103.55 | 198.7K | 27,400 | — | ↗ |
| 2023-12-01 | WEITZMAN DEBORAH | Officer | F-InKind | D | Common Shares | 638 | 107.08 | 68.3K | 34,564 | — | ↗ |
| 2023-12-01 | Snow Ola M | Officer | F-InKind | D | Common Shares | 382 | 107.08 | 40.9K | 24,842 | — | ↗ |
| 2023-12-01 | Scherer Mary C. | Officer | F-InKind | D | Common Shares | 217 | 107.08 | 23.2K | 10,432 | — | ↗ |
| 2023-11-27 | WEITZMAN DEBORAH | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 15,373 | 66.43 | 1.02M | 0 | — | ↗ |
| 2023-11-15 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 5,185 | 102.90 | 533.5K | 79,680 | — | ↗ |
| 2023-11-15 | MUNDKUR CHRISTINE | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 4,739 | — | ↗ |
| 2023-11-15 | Killefer Nancy | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 24,827 | — | ↗ |
| 2023-11-15 | KENNY GREGORY B | Director | A-Award | A | Common Shares | 3,193 | 0.00 | — | 59,680 | — | ↗ |
| 2023-11-15 | JOHRI AKHIL | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 20,071 | — | ↗ |
| 2023-11-15 | Hall Patricia Hemingway | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 29,467 | — | ↗ |
| 2023-11-15 | Evans David C | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 12,576 | — | ↗ |
| 2023-11-15 | Edison Sheri H. | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 12,051 | — | ↗ |
| 2023-11-15 | Chandrasekaran Sujatha | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 4,739 | — | ↗ |
| 2023-11-15 | Brennan Michelle | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 5,289 | — | ↗ |
| 2023-11-15 | Barg Steven | Director | A-Award | A | Common Shares | 1,965 | 0.00 | — | 4,739 | — | ↗ |
| 2023-08-28 | WEITZMAN DEBORAH | Officer | S-Sale | D | Common Shares | 6,712 | 89.81 | 602.8K | 44,202 | — | ↗ |
| 2023-08-18 | Scherer Mary C. | Officer | S-Sale | D | Common Shares | 20,695 | 86.27 | 1.79M | 10,649 | — | ↗ |
| 2023-08-17 | Snow Ola M | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 3,907 | 71.43 | 279.1K | 0 | — | ↗ |
| 2023-08-17 | Mayer Jessica L | Officer | S-Sale | D | Common Shares | 10,668 | 87.68 | 935.4K | 84,865 | — | ↗ |
| 2023-08-17 | Mason Stephen M | Officer | S-Sale | D | Common Shares | 7,977 | 88.42 | 705.3K | 37,355 | — | ↗ |
| 2023-08-17 | Greene Michelle D. | Officer | S-Sale | D | Common Shares | 2,000 | 86.79 | 173.6K | 20,814 | — | ↗ |
| 2023-08-16 | WEITZMAN DEBORAH | Officer | A-Award | A | Common Shares | 15,487 | 0.00 | — | 44,202 | — | ↗ |
| 2023-08-16 | Snow Ola M | Officer | A-Award | A | Common Shares | 9,956 | 0.00 | — | 48,179 | — | ↗ |
| 2023-08-16 | Scherer Mary C. | Officer | A-Award | A | Common Shares | 1,659 | 0.00 | — | 19,884 | — | ↗ |
| 2023-08-16 | Mayer Jessica L | Officer | M-Exempt | A | Common Shares | 973 | 84.27 | 82.0K | 125,678 | — | ↗ |
| 2023-08-16 | Mason Stephen M | Officer | A-Award | A | Common Shares | 13,274 | 0.00 | — | 74,855 | — | ↗ |
| 2023-08-16 | Hollar Jason M. | Officer | A-Award | A | Common Shares | 53,097 | 0.00 | — | 214,811 | — | ↗ |
| 2023-08-16 | Greene Michelle D. | Officer | A-Award | A | Common Shares | 10,398 | 0.00 | — | 22,814 | — | ↗ |
| 2023-08-16 | Alt Aaron E | Officer | A-Award | A | Common Shares | 16,593 | 0.00 | — | 29,319 | — | ↗ |
| 2023-08-15 | WEITZMAN DEBORAH | Officer | F-InKind | D | Common Shares | 10,966 | 92.99 | 1.02M | 28,715 | — | ↗ |
| 2023-08-15 | Snow Ola M | Officer | F-InKind | D | Common Shares | 15,031 | 92.99 | 1.40M | 38,223 | — | ↗ |
| 2023-08-15 | Scherer Mary C. | Officer | F-InKind | D | Common Shares | 2,852 | 92.99 | 265.2K | 18,225 | — | ↗ |
| 2023-08-15 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 20,010 | 92.99 | 1.86M | 110,289 | — | ↗ |
| 2023-08-15 | Mason Stephen M | Officer | F-InKind | D | Common Shares | 25,701 | 92.99 | 2.39M | 61,581 | — | ↗ |
| 2023-08-15 | Hollar Jason M. | Officer | F-InKind | D | Common Shares | 20,771 | 92.99 | 1.93M | 161,714 | — | ↗ |
| 2023-08-15 | Greene Michelle D. | Officer | F-InKind | D | Common Shares | 1,239 | 92.99 | 115.2K | 12,416 | — | ↗ |
| 2023-08-07 | WEITZMAN DEBORAH | Officer | A-Award | A | Common Shares | 12,760 | 0.00 | — | 39,681 | — | ↗ |
| 2023-08-07 | Snow Ola M | Officer | A-Award | A | Common Shares | 22,969 | 0.00 | — | 53,254 | — | ↗ |
| 2023-08-07 | Scherer Mary C. | Officer | A-Award | A | Common Shares | 2,552 | 0.00 | — | 21,077 | — | ↗ |
| 2023-08-07 | Mayer Jessica L | Officer | A-Award | A | Common Shares | 28,329 | 0.00 | — | 130,104 | — | ↗ |
| 2023-08-07 | Mason Stephen M | Officer | A-Award | A | Common Shares | 38,282 | 0.00 | — | 87,282 | — | ↗ |
| 2023-08-07 | Hollar Jason M. | Officer | A-Award | A | Common Shares | 38,282 | 0.00 | — | 182,485 | — | ↗ |
| 2023-06-30 | DOWNEY BRUCE | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-15 | Hollar Jason M. | Officer | F-InKind | D | Common Shares | 3,037 | 84.77 | 257.4K | 144,203 | — | ↗ |
| 2023-03-15 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 1,336 | 70.72 | 94.5K | 101,775 | — | ↗ |
| 2023-03-15 | Greene Michelle D. | Officer | F-InKind | D | Common Shares | 669 | 70.72 | 47.3K | 13,655 | — | ↗ |
| 2023-02-15 | Alt Aaron E | Officer | A-Award | A | Common Shares | 12,726 | 0.00 | — | 12,726 | — | ↗ |
| 2023-02-10 | Alt Aaron E | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-01 | WEITZMAN DEBORAH | Officer | F-InKind | D | Common Shares | 380 | 80.17 | 30.5K | 26,921 | — | ↗ |
| 2022-12-01 | Snow Ola M | Officer | F-InKind | D | Common Shares | 596 | 80.17 | 47.8K | 29,961 | — | ↗ |
| 2022-11-15 | Mayer Jessica L | Officer | F-InKind | D | Common Shares | 5,185 | 75.21 | 390.0K | 120,827 | — | ↗ |
| 2022-11-15 | Brennan Michelle | Director | P-Purchase | A | Common Shares | 200 | 74.72 | 14.9K | 3,324 | — | ↗ |
| 2022-11-14 | Brennan Michelle | Director | P-Purchase | A | Common Shares | 200 | 76.30 | 15.3K | 3,124 | — | ↗ |
| 2022-11-10 | Brennan Michelle | Director | P-Purchase | A | Common Shares | 150 | 79.74 | 12.0K | 2,924 | — | ↗ |
| 2022-11-09 | MUNDKUR CHRISTINE | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 2,774 | — | ↗ |
| 2022-11-09 | Killefer Nancy | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 22,862 | — | ↗ |
| 2022-11-09 | KENNY GREGORY B | Director | A-Award | A | Common Shares | 3,867 | 0.00 | — | 56,487 | — | ↗ |
| 2022-11-09 | JOHRI AKHIL | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 18,106 | — | ↗ |
| 2022-11-09 | Hall Patricia Hemingway | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 27,502 | — | ↗ |
| 2022-11-09 | Evans David C | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 10,611 | — | ↗ |
| 2022-11-09 | Edison Sheri H. | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 10,086 | — | ↗ |
| 2022-11-09 | DOWNEY BRUCE | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 53,929 | — | ↗ |
| 2022-11-09 | Chandrasekaran Sujatha | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 2,774 | — | ↗ |
| 2022-11-09 | COX CARRIE SMITH | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 41,631 | — | ↗ |
| 2022-11-09 | Brennan Michelle | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 2,774 | — | ↗ |
| 2022-11-09 | Barg Steven | Director | A-Award | A | Common Shares | 2,308 | 0.00 | — | 2,774 | — | ↗ |
| 2022-11-07 | Snow Ola M | Officer | G-Gift | D | Common Shares | 630 | 0.00 | — | 30,557 | — | ↗ |
| 2022-11-07 | Mason Stephen M | Officer | M-Exempt | A | Common Shares | 12,176 | 66.43 | 808.9K | 110,216 | — | ↗ |
| 2022-10-18 | SCARBOROUGH DEAN A | Director | A-Award | A | Phantom Stock | 406 | 70.66 | 28.7K | 6,659 | — | ↗ |
| 2022-09-15 | MUNDKUR CHRISTINE | Director | A-Award | A | Common Shares | 466 | 0.00 | — | 466 | — | ↗ |
| 2022-09-15 | Chandrasekaran Sujatha | Director | A-Award | A | Common Shares | 466 | 0.00 | — | 466 | — | ↗ |
| 2022-09-15 | Brennan Michelle | Director | A-Award | A | Common Shares | 466 | 0.00 | — | 466 | — | ↗ |
| 2022-09-06 | MUNDKUR CHRISTINE | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-06 | Chandrasekaran Sujatha | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-06 | Brennan Michelle | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-26 | Greene Michelle D. | Officer | — | D | Common Shares | 0 | 0.00 | — | 14,324 | — | ↗ |
| 2022-08-15 | Snow Ola M | Officer | F-InKind | D | Common Shares | 12,803 | 69.32 | 887.5K | 50,777 | — | ↗ |
| 2022-08-15 | Rice Brian S | Officer | F-InKind | D | Common Shares | 9,850 | 69.32 | 682.8K | 37,850 | — | ↗ |
| 2022-08-15 | Mayer Jessica L | Officer | M-Exempt | A | Common Shares | 442 | 39.81 | 17.6K | 126,351 | — | ↗ |
| 2022-08-15 | Mason Stephen M | Officer | A-Award | A | Common Shares | 17,150 | 0.00 | — | 115,931 | — | ↗ |
| 2022-08-15 | Kaufmann Michael C | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 96,291 | 0.00 | — | 0 | — | ↗ |
| 2022-08-15 | Hollar Jason M. | Officer | F-InKind | D | Common Shares | 8,206 | 69.32 | 568.8K | 147,240 | — | ↗ |
| 2022-08-15 | Holcomb Michele | Officer | F-InKind | D | Common Shares | 9,687 | 69.32 | 671.5K | 44,491 | — | ↗ |
| 2022-08-15 | English Patricia M | Officer | A-Award | A | Common Shares | 2,144 | 0.00 | — | 10,313 | — | ↗ |
| 2022-08-15 | CRAWFORD VICTOR L. | Officer | A-Award | A | Common Shares | 17,150 | 0.00 | — | 135,651 | — | ↗ |
| 2022-08-09 | Snow Ola M | Officer | A-Award | A | Common Shares | 16,607 | 0.00 | — | 53,576 | — | ↗ |
| 2022-08-09 | Rice Brian S | Officer | A-Award | A | Common Shares | 13,286 | 0.00 | — | 47,700 | — | ↗ |
| 2022-08-09 | Mayer Jessica L | Officer | A-Award | A | Common Shares | 23,250 | 0.00 | — | 128,061 | — | ↗ |
| 2022-08-09 | Mason Stephen M | Officer | A-Award | A | Common Shares | 29,893 | 0.00 | — | 98,781 | — | ↗ |
| 2022-08-09 | Kaufmann Michael C | Officer | A-Award | A | Common Shares | 132,857 | 0.00 | — | 672,988 | — | ↗ |
| 2022-08-09 | Hollar Jason M. | Officer | A-Award | A | Common Shares | 18,999 | 0.00 | — | 71,124 | — | ↗ |
| 2022-08-09 | Holcomb Michele | Officer | A-Award | A | Common Shares | 13,286 | 0.00 | — | 54,178 | — | ↗ |
| 2022-08-09 | CRAWFORD VICTOR L. | Officer | A-Award | A | Common Shares | 36,536 | 0.00 | — | 118,501 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jason M. Hollar Chief Executive Officer | 1.49M | — | 13.43M | — | 3.55M | 500.7K | 18.98M | 70.78% | ↗ |
| 2 | 2025 | Aaron E. Alt Chief Financial Officer | 871.2K | — | 3.98M | — | 1.30M | 57.8K | 6.21M | 64.05% | ↗ |
| 3 | 2025 | Deborah L. Weitzman Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | 741.9K | — | 3.77M | — | 964.5K | 30.2K | 5.51M | 68.47% | ↗ |
| 4 | 2025 | Jessica L. Mayer Chief Legal and Compliance Officer | 716.9K | — | 3.20M | — | 975.0K | 30.5K | 4.93M | 65.03% | ↗ |
| 5 | 2025 | Stephen M. Mason Chief Executive Officer, Global Medical Products and Distribution Segment | 741.9K | — | 3.36M | — | 593.5K | 51.7K | 4.75M | 70.77% | ↗ |
| 6 | 2024 | Jason M. Hollar Chief Executive Officer | 1.43M | — | 20.64M | — | 3.11M | 464.0K | 25.65M | 80.47% | ↗ |
| 7 | 2024 | Stephen M. Mason Chief Executive Officer, Global Medical Products and Distribution Segment | 721.0K | — | 5.97M | — | 627.3K | 16.2K | 7.34M | 81.40% | ↗ |
| 8 | 2024 | Aaron E. Alt Chief Financial Officer | 846.0K | — | 4.82M | — | 1.15M | 18.7K | 6.84M | 70.50% | ↗ |
| 9 | 2024 | Deborah L. Weitzman Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | 709.2K | — | 3.60M | — | 758.8K | 21.9K | 5.09M | 70.72% | ↗ |
| 10 | 2024 | Jessica L. Mayer Chief Legal and Compliance Officer | 696.0K | — | 3.08M | — | 863.1K | 13.8K | 4.66M | 66.23% | ↗ |
| 11 | 2023 | Jason M. Hollar Chief Executive Officer | 1.25M | — | 14.83M | — | 2.38M | 328.3K | 18.79M | 78.93% | ↗ |
| 12 | 2023 | Jason M. Hollar Chief Executive Officer and Former Chief Financial Officer | 1.25M | — | 14.83M | — | 2.38M | 318.3K | 18.78M | 78.98% | ↗ |
| 13 | 2023 | Aaron E. Alt Chief Financial Officer | 375.2K | 1.00M | 3.82M | — | 544.8K | 265.0K | 6.00M | 63.59% | ↗ |
| 14 | 2023 | Victor L. Crawford Former Chief Executive Officer, Pharmaceutical Segment | 280.7K | — | 3.18M | — | — | 1.30M | 4.77M | 66.76% | ↗ |
| 15 | 2023 | Stephen M. Mason Chief Executive Officer, Global Medical Products and Distribution Segment | 696.0K | — | 3.18M | — | 522.0K | 20.7K | 4.42M | 71.99% | ↗ |
| 16 | 2023 | Stephen M. Mason Chief Executive Officer, Medical Segment | 696.0K | — | 3.18M | — | 522.0K | 13.2K | 4.42M | 72.12% | ↗ |
| 17 | 2023 | Jessica L. Mayer Chief Legal and Compliance Officer | 666.9K | — | 2.92M | — | 800.3K | 13.8K | 4.40M | 66.34% | ↗ |
| 18 | 2023 | Deborah L. Weitzman Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | 606.1K | — | 2.67M | — | 774.0K | 19.0K | 4.07M | 65.64% | ↗ |
| 19 | 2023 | Deborah L. Weitzman Chief Executive Officer, Pharmaceutical Segment | 606.1K | — | 2.67M | — | 774.0K | 17.8K | 4.07M | 65.66% | ↗ |
| 20 | 2023 | Michael C. Kaufmann Former Chief Executive Officer | 233.0K | — | — | — | — | 3.30M | 3.53M | 0.00% | ↗ |
| 21 | 2023 | Patricia M. English Former Interim Chief Financial Officer | 291.5K | — | 811.4K | — | 146.7K | 13.2K | 1.26M | 64.26% | ↗ |
| 22 | 2022 | Michael C. Kaufmann Chief Executive Officer | 1.34M | — | 11.05M | — | 805.1K | 265.6K | 13.46M | 82.08% | ↗ |
| 23 | 2022 | Michael C. Kaufmann Former Chief Executive Officer | 1.34M | — | 11.05M | — | 805.1K | 265.6K | 13.46M | 82.08% | ↗ |
| 24 | 2022 | Jessica L. Mayer Chief Legal and Compliance Officer | 616.8K | — | 4.26M | — | 244.2K | 12.4K | 5.14M | 82.99% | ↗ |
| 25 | 2022 | Jason M. Hollar Chief Executive Officer and Former Chief Financial Officer | 729.2K | — | 2.76M | — | 320.9K | 69.8K | 3.88M | 71.16% | ↗ |
| 26 | 2022 | Jason M. Hollar Chief Executive Officer | 729.2K | — | 2.76M | — | 320.9K | 69.8K | 3.88M | 71.16% | ↗ |
| 27 | 2022 | Jason M. Hollar Chief Financial Officer | 729.2K | — | 2.76M | — | 320.9K | 69.8K | 3.88M | 71.16% | ↗ |
| 28 | 2022 | Victor L. Crawford Former Chief Executive Officer, Pharmaceutical Segment | 741.3K | — | 2.76M | — | 296.5K | 12.2K | 3.81M | 72.46% | ↗ |
| 29 | 2022 | Victor L. Crawford Chief Executive Officer - Pharmaceutical Segment | 741.3K | — | 2.76M | — | 296.5K | 12.2K | 3.81M | 72.46% | ↗ |
| 30 | 2022 | Stephen M. Mason Chief Executive Officer, Medical Segment | 666.8K | — | 2.76M | — | 166.7K | 15.4K | 3.61M | 76.50% | ↗ |
| 31 | 2022 | Stephen M. Mason Chief Executive Officer, Global Medical Products and Distribution Segment | 666.8K | — | 2.76M | — | 166.7K | 15.4K | 3.61M | 76.50% | ↗ |
| 32 | 2022 | Stephen M. Mason Chief Executive Officer - Medical Segment | 666.8K | — | 2.76M | — | 166.7K | 15.4K | 3.61M | 76.50% | ↗ |
| 33 | 2021 | Michael C. Kaufmann Former Chief Executive Officer | 1.30M | — | 10.20M | — | 780.0K | 204.5K | 12.48M | 81.70% | ↗ |
| 34 | 2021 | Michael C. Kaufmann Chief Executive Officer | 1.30M | — | 10.20M | — | 780.0K | 204.5K | 12.48M | 81.70% | ↗ |
| 35 | 2021 | Victor L. Crawford Chief Executive Officer - Pharmaceutical Segment | 725.0K | — | 2.80M | — | 652.5K | 35.9K | 4.22M | 66.49% | ↗ |
| 36 | 2021 | Victor L. Crawford Former Chief Executive Officer, Pharmaceutical Segment | 725.0K | — | 2.80M | — | 652.5K | 35.9K | 4.22M | 66.49% | ↗ |
| 37 | 2021 | Jason M. Hollar Chief Financial Officer | 700.0K | — | 2.55M | — | 630.0K | 71.4K | 3.95M | 64.53% | ↗ |
| 38 | 2021 | Jason M. Hollar Chief Executive Officer and Former Chief Financial Officer | 700.0K | — | 2.55M | — | 630.0K | 71.4K | 3.95M | 64.53% | ↗ |
| 39 | 2021 | Stephen M. Mason Chief Executive Officer - Medical Segment | 625.0K | — | 2.55M | — | 562.5K | 17.3K | 3.75M | 67.91% | ↗ |
| 40 | 2021 | Stephen M. Mason Chief Executive Officer, Medical Segment | 625.0K | — | 2.55M | — | 562.5K | 17.3K | 3.75M | 67.91% | ↗ |
| 41 | 2021 | Jessica L. Mayer Chief Legal and Compliance Officer | 575.0K | — | 1.89M | — | 465.8K | 11.8K | 2.94M | 64.19% | ↗ |
| 42 | 2020 | Michael C. Kaufmann Chief Executive Officer | 1.29M | — | 10.24M | — | 2.55M | 143.0K | 14.22M | 72.03% | ↗ |
| 43 | 2020 | Victor L. Crawford Chief Executive Officer - Pharmaceutical Segment | 721.7K | — | 2.82M | — | 909.3K | 14.3K | 4.46M | 63.12% | ↗ |
| 44 | 2020 | Jason M. Hollar Chief Financial Officer | 124.3K | 1.55M | 2.07M | — | 149.2K | 213.1K | 4.10M | 50.38% | ↗ |
| 45 | 2020 | Stephen M. Mason Chief Executive Officer - Medical Segment | 511.7K | — | 2.30M | — | 586.3K | 21.4K | 3.42M | 67.30% | ↗ |
| 46 | 2020 | Jessica L. Mayer Chief Legal and Compliance Officer | 547.3K | — | 1.79M | — | 559.1K | 15.9K | 2.91M | 61.49% | ↗ |
| 47 | 2020 | David C. Evans Former interim Chief Financial Officer | 2.18M | — | — | — | — | 26.9K | 2.21M | 0.00% | ↗ |
| 48 | 2020 | Jorge M. Gomez Former Chief Financial Officer | 65.6K | — | — | — | — | 3.0K | 68.5K | 0.00% | ↗ |
| 49 | 2019 | Michael C. Kaufmann Chief Executive Officer | 1.19M | — | 12.11M | — | 2.13M | 140.6K | 15.57M | 77.78% | ↗ |
| 50 | 2019 | Victor L. Crawford Chief Executive Officer - Pharmaceutical Segment | 443.0K | 2.50M | 3.10M | — | 502.4K | 184.7K | 6.73M | 46.03% | ↗ |
| 51 | 2019 | Jon L. Giacomin Former Chief Executive Officer - Medical Segment | 805.3K | — | 3.04M | — | — | 26.4K | 3.87M | 78.50% | ↗ |
| 52 | 2019 | Craig S. Morford Former Chief Legal and Compliance Officer | 463.9K | — | 2.28M | — | 425.8K | 19.5K | 3.19M | 71.47% | ↗ |
| 53 | 2019 | Jorge M. Gomez Former Chief Financial Officer | 593.3K | — | 2.53M | — | — | 26.8K | 3.15M | 80.32% | ↗ |
| 54 | 2019 | Jessica L. Mayer Chief Legal and Compliance Officer | 429.9K | — | 2.15M | — | 364.9K | 19.7K | 2.97M | 72.55% | ↗ |
| 55 | 2018 | George S. Barrett Executive Chairman of the Board and Former Chairman and Chief Executive Officer | 1.35M | — | 6.33M | 3.16M | 2.07M | 189.7K | 13.11M | 72.42% | ↗ |
| 56 | 2018 | Michael C. Kaufmann Chief Executive Officer | 955.7K | — | 4.90M | 948.7K | 1.52M | 100.4K | 8.42M | 69.43% | ↗ |
| 57 | 2018 | Michael C. Kaufmann Chief Executive Officer and Former Chief Financial Officer | 955.7K | — | 4.90M | 948.7K | 1.52M | 100.4K | 8.42M | 69.43% | ↗ |
| 58 | 2018 | Jon L. Giacomin Chief Executive Officer - Medical Segment | 697.1K | — | 2.90M | 948.7K | 853.2K | 36.1K | 5.44M | 70.81% | ↗ |
| 59 | 2018 | Jon L. Giacomin Former Chief Executive Officer - Medical Segment | 697.1K | — | 2.90M | 948.7K | 853.2K | 36.1K | 5.44M | 70.81% | ↗ |
| 60 | 2018 | Donald M. Casey Jr. Former Chief Executive Officer - Medical Segment | 440.4K | — | 1.90M | 948.7K | — | 3.1K | 3.29M | 86.53% | ↗ |
| 61 | 2018 | Craig S. Morford Former Chief Legal and Compliance Officer | 585.2K | — | 1.11M | 593.3K | 608.8K | 31.5K | 2.93M | 58.17% | ↗ |
| 62 | 2018 | Craig S. Morford Chief Legal and Compliance Officer | 585.2K | — | 1.11M | 593.3K | 608.8K | 31.5K | 2.93M | 58.17% | ↗ |
| 63 | 2018 | Patricia B. Morrison Retired Executive Vice President, Customer Support Services and Chief Information Officer | 530.4K | — | 1.10M | 734.8K | 432.8K | 30.7K | 2.82M | 64.81% | ↗ |
| 64 | 2018 | Jorge M. Gomez Chief Financial Officer | 478.1K | — | 1.29M | 163.5K | 387.4K | 37.5K | 2.36M | 61.76% | ↗ |
| 65 | 2018 | Jorge M. Gomez Former Chief Financial Officer | 478.1K | — | 1.29M | 163.5K | 387.4K | 37.5K | 2.36M | 61.76% | ↗ |
| 66 | 2017 | George S. Barrett Executive Chairman of the Board and Former Chairman and Chief Executive Officer | 1.32M | — | 6.33M | 3.17M | — | 165.5K | 10.99M | 86.48% | ↗ |
| 67 | 2017 | George S. Barrett Chairman and Chief Executive Officer | 1.32M | — | 6.33M | 3.17M | — | 165.5K | 10.99M | 86.48% | ↗ |
| 68 | 2017 | Michael C. Kaufmann Chief Executive Officer and Former Chief Financial Officer | 746.4K | 186.6K | 1.95M | 997.4K | — | 15.0K | 3.89M | 75.65% | ↗ |
| 69 | 2017 | Michael C. Kaufmann Chief Financial Officer | 746.4K | 186.6K | 1.95M | 997.4K | — | 15.0K | 3.89M | 75.65% | ↗ |
| 70 | 2017 | Michael C. Kaufmann Chief Executive Officer | 746.4K | 186.6K | 1.95M | 997.4K | — | 15.0K | 3.89M | 75.65% | ↗ |
| 71 | 2017 | Donald M. Casey Jr. Chief Executive Officer-Medical Segment | 705.0K | 176.3K | 1.95M | 997.4K | — | 10.8K | 3.84M | 76.75% | ↗ |
| 72 | 2017 | Donald M. Casey Jr. Former Chief Executive Officer - Medical Segment | 705.0K | 176.3K | 1.95M | 997.4K | — | 10.8K | 3.84M | 76.75% | ↗ |
| 73 | 2017 | Jon L. Giacomin Chief Executive Officer - Medical Segment | 567.2K | 141.8K | 1.90M | 949.9K | — | 15.0K | 3.57M | 79.74% | ↗ |
| 74 | 2017 | Jon L. Giacomin Former Chief Executive Officer - Medical Segment | 567.2K | 141.8K | 1.90M | 949.9K | — | 15.0K | 3.57M | 79.74% | ↗ |
| 75 | 2017 | Jon L. Giacomin Chief Executive Officer-Pharmaceutical Segment | 567.2K | 141.8K | 1.90M | 949.9K | — | 15.0K | 3.57M | 79.74% | ↗ |
| 76 | 2017 | Craig S. Morford Chief Legal and Compliance Officer | 552.2K | 117.3K | 1.03M | 516.6K | — | 15.0K | 2.23M | 69.37% | ↗ |
| 77 | 2017 | Craig S. Morford Former Chief Legal and Compliance Officer | 552.2K | 117.3K | 1.03M | 516.6K | — | 15.0K | 2.23M | 69.37% | ↗ |
| 78 | 2016 | George S. Barrett Chairman and Chief Executive Officer | 1.32M | — | 6.49M | 3.33M | 2.39M | 131.9K | 13.66M | 71.90% | ↗ |
| 79 | 2016 | George S. Barrett Executive Chairman of the Board and Former Chairman and Chief Executive Officer | 1.32M | — | 6.49M | 3.33M | 2.39M | 131.9K | 13.66M | 71.90% | ↗ |
| 80 | 2016 | Michael C. Kaufmann Chief Financial Officer | 721.3K | — | 1.58M | 826.4K | 880.7K | 27.3K | 4.03M | 59.58% | ↗ |
| 81 | 2016 | Michael C. Kaufmann Chief Executive Officer and Former Chief Financial Officer | 721.3K | — | 1.58M | 826.4K | 880.7K | 27.3K | 4.03M | 59.58% | ↗ |
| 82 | 2016 | Donald M. Casey Jr. Former Chief Executive Officer — Medical Segment | 671.3K | — | 1.51M | 806.4K | 894.2K | 22.8K | 3.90M | 59.27% | ↗ |
| 83 | 2016 | Donald M. Casey Jr. Chief Executive Officer — Medical Segment | 671.3K | — | 1.51M | 806.4K | 894.2K | 22.8K | 3.90M | 59.27% | ↗ |
| 84 | 2016 | Donald M. Casey Jr. Chief Executive Officer—Medical Segment | 671.3K | — | 1.51M | 806.4K | 894.2K | 22.8K | 3.90M | 59.27% | ↗ |
| 85 | 2016 | Jon L. Giacomin Chief Executive Officer—Pharmaceutical Segment | 542.6K | — | 1.40M | 701.2K | 602.3K | 27.8K | 3.27M | 64.18% | ↗ |
| 86 | 2016 | Jon L. Giacomin Chief Executive Officer — Medical Segment | 542.6K | — | 1.40M | 701.2K | 602.3K | 27.8K | 3.27M | 64.18% | ↗ |
| 87 | 2016 | Jon L. Giacomin Chief Executive Officer — Pharmaceutical Segment | 542.6K | — | 1.40M | 701.2K | 602.3K | 27.8K | 3.27M | 64.18% | ↗ |
| 88 | 2016 | Craig S. Morford Chief Legal and Compliance Officer | 531.3K | — | 1.62M | 420.7K | 576.5K | 37.6K | 3.19M | 64.05% | ↗ |
| 89 | 2015 | George S. Barrett Chairman and Chief Executive Officer | 1.32M | — | 5.98M | 3.32M | 2.51M | 135.2K | 13.27M | 70.11% | ↗ |
| 90 | 2015 | Michael C. Kaufmann Chief Financial Officer | 688.6K | — | 4.54M | 841.0K | 1.05M | 36.3K | 7.16M | 75.16% | ↗ |
| 91 | 2015 | Donald M. Casey Jr. Chief Executive Officer — Medical Segment | 650.0K | — | 3.01M | 806.0K | 618.1K | 31.7K | 5.11M | 74.57% | ↗ |
| 92 | 2015 | Donald M. Casey Jr. Chief Executive Officer—Medical Segment | 650.0K | — | 3.01M | 806.0K | 618.1K | 31.7K | 5.11M | 74.57% | ↗ |
| 93 | 2015 | Jeffrey W. Henderson Former Chief Financial Officer | 794.0K | — | 1.75M | — | 1.06M | 35.7K | 3.64M | 48.14% | ↗ |
| 94 | 2015 | Jon L. Giacomin Chief Executive Officer—Pharmaceutical Segment | 480.7K | — | 1.24M | 629.3K | 679.7K | 37.2K | 3.06M | 60.92% | ↗ |
| 95 | 2015 | Jon L. Giacomin Chief Executive Officer — Pharmaceutical Segment | 480.7K | — | 1.24M | 629.3K | 679.7K | 37.2K | 3.06M | 60.92% | ↗ |
| 96 | 2015 | Craig S. Morford Chief Legal and Compliance Officer | 510.0K | — | 800.0K | 400.5K | 559.6K | 35.5K | 2.31M | 52.07% | ↗ |
| 97 | 2014 | George S. Barrett Chairman and Chief Executive Officer | 1.31M | — | 5.53M | 2.87M | 2.60M | 132.4K | 12.45M | 67.47% | ↗ |
| 98 | 2014 | Jeffrey W. Henderson Chief Financial Officer | 756.9K | — | 1.63M | 816.5K | 1.15M | 32.2K | 4.39M | 55.79% | ↗ |
| 99 | 2014 | Jeffrey W. Henderson Former Chief Financial Officer | 756.9K | — | 1.63M | 816.5K | 1.15M | 32.2K | 4.39M | 55.79% | ↗ |
| 100 | 2014 | Michael C. Kaufmann Chief Executive Officer — Pharmaceutical Segment | 647.7K | — | 1.40M | 699.9K | 1.23M | 32.3K | 4.01M | 52.38% | ↗ |
| 101 | 2014 | Michael C. Kaufmann Chief Financial Officer | 647.7K | — | 1.40M | 699.9K | 1.23M | 32.3K | 4.01M | 52.38% | ↗ |
| 102 | 2014 | Donald M. Casey Jr. Chief Executive Officer — Medical Segment | 647.7K | — | 1.47M | 769.9K | 544.1K | 28.2K | 3.46M | 64.74% | ↗ |
| 103 | 2014 | Craig S. Morford Chief Legal and Compliance Officer | 508.5K | — | 799.9K | 399.9K | 553.0K | 32.4K | 2.29M | 52.31% | ↗ |
| 104 | 2013 | George S. Barrett Chairman and Chief Executive Officer | 1.29M | — | 5.34M | 2.70M | 2.02M | 137.6K | 11.47M | 69.99% | ↗ |
| 105 | 2013 | Jeffrey W. Henderson Former Chief Financial Officer | 740.0K | — | 1.67M | 836.1K | 846.2K | 29.1K | 4.13M | 60.85% | ↗ |
| 106 | 2013 | Jeffrey W. Henderson Chief Financial Officer | 740.0K | — | 1.67M | 836.1K | 846.2K | 29.1K | 4.13M | 60.85% | ↗ |
| 107 | 2013 | Michael C. Kaufmann Chief Executive Officer — Pharmaceutical Segment | 635.0K | — | 1.51M | 784.9K | 714.4K | 28.9K | 3.67M | 62.43% | ↗ |
| 108 | 2013 | Michael C. Kaufmann Chief Financial Officer | 635.0K | — | 1.51M | 784.9K | 714.4K | 28.9K | 3.67M | 62.43% | ↗ |
| 109 | 2013 | Donald M. Casey Jr. Chief Executive Officer — Medical Segment | 635.0K | — | 1.40M | 682.5K | 525.8K | 37.0K | 3.28M | 63.49% | ↗ |
| 110 | 2013 | Craig S. Morford Chief Legal and Compliance Officer | 500.0K | — | 820.0K | 409.5K | 453.8K | 29.1K | 2.21M | 55.57% | ↗ |
| 111 | 2012 | George S. Barrett Chairman and Chief Executive Officer | 1.28M | — | 5.14M | 2.86M | 1.81M | 123.2K | 11.21M | 71.36% | ↗ |
| 112 | 2012 | Jeffrey W. Henderson Chief Financial Officer | 736.8K | — | 1.66M | 831.5K | 722.8K | 22.8K | 3.98M | 62.73% | ↗ |
| 113 | 2012 | Michael C. Kaufmann Chief Executive Officer — Pharmaceutical Segment | 629.4K | — | 1.44M | 713.7K | 628.7K | 23.3K | 3.44M | 62.72% | ↗ |
| 114 | 2012 | Michael A. Lynch Former Chief Executive Officer — Medical Segment | 584.5K | — | 1.46M | 713.7K | 431.4K | 58.8K | 3.25M | 66.93% | ↗ |
| 115 | 2012 | Donald M. Casey Jr. Chief Executive Officer — Medical Segment | 131.9K | 500.0K | 1,000.0K | 500.1K | 118.7K | 506.1K | 2.76M | 54.42% | ↗ |
| 116 | 2012 | Craig S. Morford Chief Legal and Compliance Officer | 496.0K | — | 712.5K | 356.2K | 405.5K | 24.6K | 1.99M | 53.58% | ↗ |
| 117 | 2011 | George S. Barrett Chairman and Chief Executive Officer | 1.23M | — | 2.52M | 4.40M | 1.93M | 132.0K | 10.21M | 67.72% | ↗ |
| 118 | 2011 | George S. Barrett Chairman and Chief Executive Officer | 1.23M | — | 2.52M | 4.40M | 1.93M | 132.0K | 10.21M | 67.72% | ↗ |
| 119 | 2011 | Jeffrey W. Henderson Chief Financial Officer | 716.7K | — | 808.5K | 1.41M | 816.0K | 25.5K | 3.78M | 58.75% | ↗ |
| 120 | 2011 | Jeffrey W. Henderson Chief Financial Officer | 716.7K | — | 808.5K | 1.41M | 816.0K | 25.5K | 3.78M | 58.75% | ↗ |
| 121 | 2011 | Michael C. Kaufmann Chief Executive Officer— Pharmaceutical Segment | 596.7K | — | 669.9K | 1.17M | 804.8K | 27.8K | 3.27M | 56.27% | ↗ |
| 122 | 2011 | Michael C. Kaufmann Chief Executive Officer — Pharmaceutical Segment | 596.7K | — | 669.9K | 1.17M | 804.8K | 27.8K | 3.27M | 56.27% | ↗ |
| 123 | 2011 | Michael A. Lynch Chief Executive Officer— Medical Segment | 615.0K | — | 693.0K | 1.21M | 359.8K | 28.2K | 2.91M | 65.47% | ↗ |
| 124 | 2011 | Michael A. Lynch Former Chief Executive Officer — Medical Segment | 615.0K | — | 693.0K | 1.21M | 359.8K | 28.2K | 2.91M | 65.47% | ↗ |
| 125 | 2011 | Craig S. Morford Chief Legal and Compliance Officer | 470.9K | — | 354.4K | — | 388.5K | 26.0K | 1.24M | 28.59% | ↗ |
| 126 | 2011 | Craig S. Morford Chief Legal and Compliance Officer | 470.9K | — | 354.4K | — | 388.5K | 26.0K | 1.24M | 28.59% | ↗ |
| 127 | 2010 | George S. Barrett Chairman and Chief Executive Officer | 1.16M | 121.9K | 4.27M | 6.16M | 2.80M | 194.7K | 14.70M | 70.93% | ↗ |
| 128 | 2010 | George S. Barrett Chairman and Chief Executive Officer | 1.16M | 121.9K | 4.27M | 6.16M | 2.80M | 194.7K | 14.70M | 70.93% | ↗ |
| 129 | 2010 | R. Kerry Clark Former Chairman and Chief Executive Officer | 250.3K | 380.6K | — | — | — | 8.01M | 8.65M | 0.00% | ↗ |
| 130 | 2010 | Jeffrey W. Henderson Chief Financial Officer | 700.0K | 105.0K | 808.5K | 2.71M | 1.17M | 37.1K | 5.52M | 63.65% | ↗ |
| 131 | 2010 | Jeffrey W. Henderson Chief Financial Officer | 700.0K | 105.0K | 808.5K | 2.71M | 1.17M | 37.1K | 5.52M | 63.65% | ↗ |
| 132 | 2010 | Michael A. Lynch Former Chief Executive Officer — Medical Segment | 600.0K | 46.4K | 693.0K | 2.52M | 945.0K | 36.7K | 4.84M | 66.34% | ↗ |
| 133 | 2010 | Michael A. Lynch Chief Executive Officer— Medical Segment | 600.0K | 46.4K | 693.0K | 2.52M | 945.0K | 36.7K | 4.84M | 66.34% | ↗ |
| 134 | 2010 | Michael A. Lynch Chief Executive Officer— Medical Segment | 600.0K | 46.4K | 693.0K | 2.52M | 945.0K | 36.7K | 4.84M | 66.34% | ↗ |
| 135 | 2010 | Michael C. Kaufmann Chief Executive Officer— Pharmaceutical Segment | 567.5K | 48.5K | 646.8K | 2.44M | 970.3K | 43.6K | 4.72M | 65.44% | ↗ |
| 136 | 2010 | Michael C. Kaufmann Chief Executive Officer — Pharmaceutical Segment | 567.5K | 48.5K | 646.8K | 2.44M | 970.3K | 43.6K | 4.72M | 65.44% | ↗ |
| 137 | 2010 | Michael C. Kaufmann Chief Executive Officer— Pharmaceutical Segment | 567.5K | 48.5K | 646.8K | 2.44M | 970.3K | 43.6K | 4.71M | 65.47% | ↗ |
| 138 | 2010 | Craig S. Morford Chief Legal and Compliance Officer | 450.0K | 27.0K | 354.4K | 1.17M | 624.4K | 39.6K | 2.66M | 57.18% | ↗ |
| 139 | 2010 | Craig S. Morford Chief Legal and Compliance Officer | 450.0K | 27.0K | 354.4K | 1.17M | 624.4K | 39.6K | 2.66M | 57.18% | ↗ |
| 140 | 2009 | R. Kerry Clark Chairman of the Board and Chief Executive Officer | 1.45M | 696.0K | 4.01M | 6.77M | — | 216.6K | 13.15M | 82.03% | ↗ |
| 141 | 2009 | R. Kerry Clark Former Chairman and Chief Executive Officer | 1.45M | 696.0K | 3.04M | 4.57M | — | 216.6K | 9.97M | 76.32% | ↗ |
| 142 | 2009 | George S. Barrett Vice Chairman and Chief Executive Officer—Healthcare Supply Chain Services | 975.0K | 390.0K | 2.26M | 1.37M | — | 246.1K | 5.25M | 69.29% | ↗ |
| 143 | 2009 | Jeffrey W. Henderson Chief Financial Officer | 700.0K | 280.0K | 1.91M | 1.01M | — | 22.0K | 3.92M | 74.45% | ↗ |
| 144 | 2009 | Jeffrey W. Henderson Chief Financial Officer | 700.0K | 280.0K | 1.68M | 1.09M | — | 22.0K | 3.77M | 73.45% | ↗ |
| 145 | 2009 | George S. Barrett Chairman and Chief Executive Officer | 975.0K | 390.0K | 975.0K | 1.18M | — | 246.1K | 3.76M | 57.19% | ↗ |
| 146 | 2009 | Ivan K. Fong | 497.3K | 179.0K | 1.20M | 519.5K | — | 1.09M | 3.49M | 49.27% | ↗ |
| 147 | 2009 | David L. Schlotterbeck Vice Chairman and Chief Executive Officer—Clinical and Medical Products | 745.0K | — | 642.1K | 769.7K | — | 21.9K | 2.19M | 64.40% | ↗ |
| 148 | 2009 | Vivek Jain | 450.0K | 162.0K | 907.2K | 429.0K | — | 18.3K | 1.97M | 67.95% | ↗ |
| 149 | 2008 | R. Kerry Clark Chairman of the Board and Chief Executive Officer | 1.44M | 691.8K | — | — | 9.81M | 246.8K | 12.19M | 0.00% | ↗ |
| 150 | 2008 | R. Kerry Clark Former Chairman and Chief Executive Officer | 1.44M | 691.8K | 2.94M | 4.41M | — | 246.8K | 9.73M | 75.55% | ↗ |
| 151 | 2008 | George S. Barrett Chairman and Chief Executive Officer | 412.9K | 706.5K | 5.33M | 3.10M | — | 183.9K | 9.73M | 86.60% | ↗ |
| 152 | 2008 | George S. Barrett Vice Chairman and Chief Executive Officer—Healthcare Supply Chain Services | 412.9K | 706.5K | 963.3K | 386.6K | — | 183.9K | 2.65M | 50.88% | ↗ |
| 153 | 2008 | David L. Schlotterbeck Vice Chairman and Chief Executive Officer—Clinical and Medical Products | 741.5K | 556.1K | 315.4K | 581.1K | — | 27.9K | 2.23M | 40.11% | ↗ |
| 154 | 2007 | R. Kerry Clark Chairman of the Board and Chief Executive Officer | 1.40M | 1.12M | — | — | 8.40M | 300.4K | 12.68M | 0.00% | ↗ |
| 155 | 2007 | R. Kerry Clark President and Chief Executive Officer | 1.40M | 1.12M | 2.58M | — | 1.46M | 300.4K | 10.82M | 23.79% | ↗ |
| 156 | 2007 | Robert D. Walter Executive Chairman of the Board | 900.0K | — | 577.5K | — | 1.55M | 393.3K | 8.53M | 6.77% | ↗ |
| 157 | 2007 | Mark W. Parrish Chief Executive Officer — Healthcare Supply Chain Services | 620.5K | — | 877.7K | — | 689.9K | 37.7K | 3.41M | 25.76% | ↗ |
| 158 | 2007 | David L. Schlotterbeck Vice Chairman and Chief Executive Officer—Clinical and Medical Products | 725.0K | — | 33.2K | 1.42M | 961.0K | 103.0K | 3.25M | 44.59% | ↗ |
| 159 | 2007 | David L. Schlotterbeck Chief Executive Officer — Clinical and Medical Products | 725.0K | — | 33.2K | — | 961.0K | 103.0K | 3.25M | 1.02% | ↗ |
| 160 | 2007 | Jeffrey W. Henderson Chief Financial Officer | 653.4K | — | 757.0K | — | 788.2K | 32.4K | 3.21M | 23.57% | ↗ |
| 161 | 2006 | R. Kerry Clark President and Chief Executive Officer | 296.2K | 460.3K | 7.73M | 665.0K | — | 17.2K | 8.50M | 98.72% | ↗ |
| 162 | 2006 | Robert D. Walter Executive Chairman of the Board and Former Chief Executive Officer | 1.07M | 2.91M | 3.19M | 1.24M | — | 102.2K | 7.27M | 61.00% | ↗ |
| 163 | 2006 | Ronald K. Labrum Chairman and Chief Executive Officer—Healthcare Supply Chain Services | 632.5K | 671.7K | 1.46M | 168.6K | — | 2.85M | 5.62M | 29.00% | ↗ |
| 164 | 2006 | George L. Fotiades Former President and Chief Operating Officer | 701.9K | 400.0K | — | — | — | 3.88M | 4.98M | 0.00% | ↗ |
| 165 | 2006 | David L. Schlotterbeck Chief Executive Officer—Pharmaceutical and Medical Products | 578.7K | 778.1K | — | — | — | 2.34M | 3.70M | 0.00% | ↗ |
| 166 | 2006 | Jeffrey W. Henderson Chief Financial Officer | 552.1K | 742.5K | — | — | — | 50.8K | 1.35M | 0.00% | ↗ |
| 167 | 2005 | Robert D. Walter Executive Chairman of the Board and Former Chief Executive Officer | 1.07M | 1.59M | — | 705.0K | — | 32.1K | 2.68M | 26.26% | ↗ |
| 168 | 2005 | Robert D. Walter Chairman and Chief Executive Officer | 1.07M | 1.59M | — | — | — | 32.1K | 2.68M | 0.00% | ↗ |
| 169 | 2005 | Jeffrey W. Henderson Chief Financial Officer | 114.2K | 323.3K | 1.14M | 108.1K | — | 4.5K | 1.58M | 78.86% | ↗ |
| 170 | 2005 | George L. Fotiades President and Chief Operating Officer | 751.1K | 683.8K | — | — | — | 36.1K | 1.47M | 0.00% | ↗ |
| 171 | 2005 | George L. Fotiades Former President and Chief Operating Officer | 751.1K | 683.8K | — | — | — | 36.1K | 1.47M | 0.00% | ↗ |
| 172 | 2005 | Ronald K. Labrum Chairman and Chief Executive Officer—Healthcare Supply Chain Services | 545.0K | 392.9K | 308.1K | 105.0K | — | 30.3K | 1.28M | 32.37% | ↗ |
| 173 | 2005 | Ronald K. Labrum Chairman and Chief Executive Officer — Healthcare Supply Chain Services | 545.0K | 392.9K | 308.1K | — | — | 30.3K | 1.28M | 24.14% | ↗ |
| 174 | 2005 | Anthony J. Rucci Executive Vice President and President of Strategic Corporate Resources | 467.6K | 303.4K | 440.1K | — | — | 29.2K | 1.24M | 35.48% | ↗ |
| 175 | 2005 | David L. Schlotterbeck Chief Executive Officer—Pharmaceutical and Medical Products | 560.0K | 539.3K | — | 244.6K | — | 22.2K | 1.12M | 21.81% | ↗ |
| 176 | 2004 | Robert D. Walter Chairman and Chief Executive Officer | 1.04M | — | — | — | — | 12.3K | 1.05M | 0.00% | ↗ |
| 177 | 2004 | Robert D. Walter Executive Chairman of the Board and Former Chief Executive Officer | 1.04M | — | — | 507.1K | — | 12.3K | 1.05M | 48.30% | ↗ |
| 178 | 2004 | Ronald K. Labrum Chairman and Chief Executive Officer — Healthcare Supply Chain Services | 490.4K | — | 306.9K | — | — | 7.3K | 804.6K | 38.14% | ↗ |
| 179 | 2004 | Ronald K. Labrum Chairman and Chief Executive Officer—Healthcare Supply Chain Services | 490.4K | — | 306.9K | 85.3K | — | 7.3K | 804.6K | 48.74% | ↗ |
| 180 | 2004 | George L. Fotiades Former President and Chief Operating Officer | 627.7K | — | — | 225.0K | — | 11.3K | 639.0K | 35.21% | ↗ |
| 181 | 2004 | George L. Fotiades President and Chief Operating Officer | 627.7K | — | — | — | — | 11.3K | 639.0K | 0.00% | ↗ |
| 182 | 2004 | Anthony J. Rucci Executive Vice President and President of Strategic Corporate Resources | 445.8K | — | — | — | — | 8.9K | 454.7K | 0.00% | ↗ |
| 183 | 2003 | Robert D. Walter Chairman and Chief Executive Officer | 1.02M | 2.11M | — | — | — | 36.5K | 3.16M | 0.00% | ↗ |
| 184 | 2003 | George L. Fotiades President and Chief Operating Officer | 532.1K | 387.4K | — | — | — | 36.0K | 955.5K | 0.00% | ↗ |
| 185 | 2003 | Anthony J. Rucci Executive Vice President and President of Strategic Corporate Resources | 433.7K | 279.1K | — | — | — | 34.1K | 746.8K | 0.00% | ↗ |
| 186 | 2003 | Ronald K. Labrum Chairman and Chief Executive Officer — Healthcare Supply Chain Services | 446.7K | 247.6K | — | — | — | 29.5K | 723.8K | 0.00% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jason Hollar | Chief Executive Officer & Director | 6M | male |
| Aaron E. Alt | Chief Financial Officer | 2M | male |
| Deborah L. Weitzman | Chief Executive Officer of Pharmaceutical & Specialty Solutions Segment | 2M | female |
| Jessica L. Mayer | Chief Legal & Compliance Officer | 2M | female |
| Stephen Mason | Chief Executive Officer of GMPD segment | 1M | male |
| Patricia English | Senior Vice President | 451.3K | female |
| Valerie Christine Pitteroff | Chief Human Resources Officer | — | female |
| Ben Brinker | President of Global Operations & Supply Chain | — | male |
| Craig Cowman | President of Biopharma Solutions & Strategic Sourcing | — | male |
| Mary C. Scherer | Senior Vice President & Chief Accounting Officer | — | female |
| Matt Sims | Vice President of Investor Relations | — | — |
| Val Pitteroff | Chief Human Resources Officer | — | female |
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-10-24 | 2025-10-29 | Marjorie Taylor Greene | GA14 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-09-05 | 2025-10-03 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-05-14 | 2025-05-20 | Marjorie Taylor Greene | GA14 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-05-05 | 2025-05-07 | Marjorie Taylor Greene | GA14 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-08 | 2025-05-08 | Rob Bresnahan | PA08 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-03-17 | 2025-03-20 | Marjorie Taylor Greene | GA14 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-01-21 | 2025-01-28 | Marjorie Taylor Greene | GA14 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-09-20 | 2024-09-23 | Marjorie Taylor Greene | GA14 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-09-04 | 2024-09-06 | John James | MI10 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2024-06-03 | 2024-09-02 | John James | MI10 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-05-02 | 2024-09-02 | John James | MI10 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-02-13 | 2024-03-06 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2024-01-12 | 2024-02-15 | Jonathan Jackson | IL01 | Joint | Purchase | $50,001 - $100,000 | ↗ |
| 2024-01-10 | 2024-02-05 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-09-06 | 2023-10-06 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-06-29 | 2023-07-11 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-02-10 | 2023-03-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-01-11 | 2023-02-07 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2022-12-06 | 2023-01-03 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-08-03 | 2022-09-14 | Kathy Manning | NC06 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CAH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
